[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Bastida Vilá P, Olivé Oliveras T, Díaz de Heredia Rubio C, Ortega Aramburu JJ: [Transient neonatal myeloproliferative disorder in the absence of Down syndrome]. An Pediatr (Barc); 2004 Dec;61(6):546-50
Genetic Alliance. consumer health - Down Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transient neonatal myeloproliferative disorder in the absence of Down syndrome].
  • [Transliterated title] Síndrome mieloproliferativo transitorio neonatal en ausencia de síndrome de Down.
  • Transient neonatal leukemia or transient neonatal myeloproliferative disorder is commonly associated with Down syndrome.
  • However, 25 % of patients will subsequently develop acute megakaryoblastic leukemia or myelodysplastic syndrome.
  • They received support treatment only without chemotherapy.
  • Caution must be exercised before initiating chemotherapy in these patients.
  • We discuss the differential diagnosis with congenital leukemia and the prognostic and therapeutic implications that this entails.
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Infant, Newborn. Leukemia / congenital. Leukemia / diagnosis. Prognosis. Remission, Spontaneous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15574256.001).
  • [ISSN] 1695-4033
  • [Journal-full-title] Anales de pediatría (Barcelona, Spain : 2003)
  • [ISO-abbreviation] An Pediatr (Barc)
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


2. Costa C, Rocha G, Grilo M, Bianchi R, Sotto Mayor T, Monteiro J, Guimarães H: [Neonatal tumors]. Acta Med Port; 2010 May-Jun;23(3):405-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neonatal tumors].
  • [Transliterated title] Tumores no período neonatal.
  • INTRODUCTION: Tumors affecting the fetus and newborn differ from those found in older children and adults, leading to new diagnostic and therapeutic challenges.
  • AIM: To evaluate the main clinical aspects related to neonatal tumors.
  • RESULTS: Total = 32 cases, 16M/16F, birth weight: 3146 g (965-4590), gestational age 38 weeks (28-41), seven (22%) preterm, C-section rate 75% (n = 24), two with EXIT procedure.
  • DIAGNOSIS: Teratoma (n = 8); lymphangioma (n = 7), neuroblastoma (n = 6), haemangioma (n = 5), other solid tumors (n = 6); acute lymphoblastic leukemia (n = 1).
  • Chemotherapy (n = 5), according to the <<European Infant Neuroblastoma Study>> (n = 2), surgical resection (n = 4).
  • Acute lymphoblast leukemia (n = 1), deceased.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20654259.001).
  • [ISSN] 1646-0758
  • [Journal-full-title] Acta médica portuguesa
  • [ISO-abbreviation] Acta Med Port
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Portugal
  •  go-up   go-down


3. López Almaraz R, Villafruela Alvarez C, Rodríguez Luis J, Doménech Martínez E: [Neonatal neoplasms: a single-centre experience]. An Pediatr (Barc); 2006 Dec;65(6):529-35

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neonatal neoplasms: a single-centre experience].
  • INTRODUCTION: Malignant tumors are uncommon in the neonatal period and benign tumors may have malignant potential.
  • PATIENTS AND METHODS: The medical records of patients with neoplasms diagnosed during the neonatal period in the previous 25 years in our hospital were retrospectively reviewed.
  • The variables analyzed were the percentage of neonatal neoplasms among the total number of cancer cases in children aged less than 14 years, their incidence among all the newborns in our hospital, sex, year of diagnosis, age at clinical diagnosis, the presence or absence of prenatal diagnosis, type of tumor (histologic diagnosis), association with syndromes or other congenital anomalies, treatment, and long-term outcome.
  • RESULTS: Of 260 neoplasms diagnosed in our unit from 1980, 16 (6.1 %) were diagnosed in the neonatal period.
  • The incidence of neonatal neoplasms was estimated to be 276.5 per million live births.
  • A further five newborns were diagnosed at the initial neonatal examination.
  • Histologic diagnoses were neuroblastoma (n = 5; 31.2 %), teratoma/ germ cell tumor (n = 4; 25 %), soft tissue sarcoma (one fibrosarcoma of the thigh and two hemangiopericytoma of the back and heart; 18.8 %), and one case each of mesoblastic nephroma, cerebral tumor (ependymoblastoma), melanoma (associated with giant congenital melanocytic nevi), and acute leukemia (associated with Down syndrome).
  • Treatment consisted of surgery alone (n = 10; 62.5 %) and surgery plus chemotherapy (n = 5; 31.2 %); one patient received no treatment.
  • CONCLUSIONS: The neoplasms most frequently diagnosed in the neonatal period were solid tumors, mainly neuroblastoma and teratomas/germ cell tumors; 12.5 % were associated with syndromes or congenital anomalies.
  • Most of the neoplasms responded to therapy, mainly surgery, and long-term outcome was favorable.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] An Pediatr (Barc). 2007 Jul;67(1):85-6 [17663916.001]
  • (PMID = 17194321.001).
  • [ISSN] 1695-4033
  • [Journal-full-title] Anales de pediatría (Barcelona, Spain : 2003)
  • [ISO-abbreviation] An Pediatr (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


Advertisement
4. Koleba T, Ensom MH: Pharmacokinetics of intravenous immunoglobulin: a systematic review. Pharmacotherapy; 2006 Jun;26(6):813-27
MedlinePlus Health Information. consumer health - Clinical Trials.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Intravenous immunoglobulin (IGIV) is used in the treatment of a wide variety of immune disorders.
  • RESULTS: Data elements extracted from these articles included study design, number of study subjects, indication for IGIV therapy, IGIV treatment regimen (formulation, dosage, and duration), pharmacokinetic parameters (clearance, volume of distribution, elimination rate constant, and half-life), analytic methodology, pharmacokinetic model, and blood sampling times.
  • CONCLUSION: The pharmacokinetics of IGIV shows considerable intra- and interpopulation variability among patients with normal immunoglobulin levels, patients with primary immunodeficiency diseases, bone marrow transplant recipients, patients with immune deficiency due to chronic lymphocytic leukemia or multiple myeloma, very low birth weight neonates, neonates with suspected sepsis, high-risk infants in the neonatal intensive care unit, high-risk infants with cardiopulmonary disease, children with cryptogenic West or Lennox-Gastaut syndrome, women and infants with fetal alloimmune thrombocytopenia, and women with recurrent spontaneous abortions.
  • [MeSH-minor] Dose-Response Relationship, Drug. Humans. Metabolic Clearance Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16716135.001).
  • [ISSN] 0277-0008
  • [Journal-full-title] Pharmacotherapy
  • [ISO-abbreviation] Pharmacotherapy
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulins, Intravenous
  • [Number-of-references] 67
  •  go-up   go-down


5. Ting AY, Petroff BK: Tamoxifen decreases ovarian follicular loss from experimental toxicant DMBA and chemotherapy agents cyclophosphamide and doxorubicin in the rat. J Assist Reprod Genet; 2010 Nov;27(11):591-7
Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tamoxifen decreases ovarian follicular loss from experimental toxicant DMBA and chemotherapy agents cyclophosphamide and doxorubicin in the rat.
  • Cultured oocytes were exposed to chemotherapy drug doxorubicin, with or without 4-hydroxytamoxifen (4HT).
  • Cyclophosphamide tended to reduce fertility and lessened neonatal survival.
  • CONCLUSIONS: tamoxifen decreases follicle loss and improves reproductive function following exposure to ovarian toxicants including chemotherapy drugs in the female rat.
  • [MeSH-major] 9,10-Dimethyl-1,2-benzanthracene / toxicity. Antineoplastic Agents / toxicity. Cyclophosphamide / toxicity. Doxorubicin / toxicity. Ovarian Follicle / drug effects. Protective Agents / pharmacology. Tamoxifen / pharmacology
  • [MeSH-minor] Animals. Cells, Cultured. Female. Fertility / drug effects. Oocytes / drug effects. Ovary / drug effects. Ovary / pathology. Rats. Rats, Sprague-Dawley

  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Reprod Endocrinol. 1998;16(4):309-14 [10101811.001]
  • [Cites] Nat Med. 2009 Oct;15(10):1179-85 [19783996.001]
  • [Cites] Mol Endocrinol. 1999 Jun;13(6):841-50 [10379884.001]
  • [Cites] Cancer Res. 1951 Jun;11(6):474-8 [14839645.001]
  • [Cites] World J Gastroenterol. 2005 Feb 21;11(7):1060-4 [15742416.001]
  • [Cites] N Engl J Med. 2005 Jul 7;353(1):64-73 [16000356.001]
  • [Cites] CA Cancer J Clin. 2005 Jul-Aug;55(4):211-28; quiz 263-4 [16020423.001]
  • [Cites] Oncol Rep. 2005 Nov;14(5):1317-21 [16211303.001]
  • [Cites] J Soc Gynecol Investig. 1999 Sep-Oct;6(5):229-39 [10554760.001]
  • [Cites] Med Oncol. 2000 Feb;17(1):39-46 [10713659.001]
  • [Cites] Toxicol Appl Pharmacol. 2000 Sep 15;167(3):191-8 [10986010.001]
  • [Cites] Mol Cell Endocrinol. 2000 Nov 27;169(1-2):123-31 [11155944.001]
  • [Cites] Nat Genet. 2001 Aug;28(4):355-60 [11455387.001]
  • [Cites] Biol Reprod. 2001 Nov;65(5):1489-95 [11673266.001]
  • [Cites] Endocrinology. 2002 Mar;143(3):1058-65 [11861533.001]
  • [Cites] Hum Reprod. 2003 Jan;18(1):90-5 [12525446.001]
  • [Cites] Reprod Biol Endocrinol. 2003 Feb 6;1:11 [12646064.001]
  • [Cites] Cancer Res. 1980 Nov;40(11):4043-7 [6451282.001]
  • [Cites] Horm Behav. 1983 Jun;17(2):208-24 [6885008.001]
  • [Cites] Pediatr Pharmacol (New York). 1984;4(4):213-21 [6522129.001]
  • [Cites] Cancer Res. 1985 Aug;45(8):3651-6 [3926307.001]
  • [Cites] Neuroendocrinology. 1986;43(6):696-705 [3762866.001]
  • [Cites] Biol Reprod. 1995 Feb;52(2):365-72 [7711205.001]
  • [Cites] Leukemia. 1995 Oct;9(10):1631-7 [7564501.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88 [9747868.001]
  • [Cites] Biol Reprod. 1998 Oct;59(4):884-9 [9746739.001]
  • [Cites] Circ Res. 1999 Feb 5;84(2):229-39 [9933255.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Nov;56(5):497-509 [15937726.001]
  • [Cites] Cell Death Differ. 2006 Sep;13(9):1466-74 [16439991.001]
  • [Cites] Ther Drug Monit. 2007 Jun;29(3):349-52 [17529893.001]
  • [Cites] Biol Reprod. 2007 Sep;77(3):442-51 [17554082.001]
  • [Cites] Oncologist. 2007 Sep;12(9):1044-54 [17914074.001]
  • [Cites] Oncologist. 2007 Sep;12(9):1055-66 [17914075.001]
  • [Cites] Cancer Treat Rev. 2007 Nov;33(7):646-55 [17499440.001]
  • [Cites] Reproduction. 2008 Jan;135(1):3-12 [18159078.001]
  • [Cites] Hum Reprod. 2008 Nov;23(11):2506-12 [18664468.001]
  • [Cites] Curr Opin Endocrinol Diabetes Obes. 2008 Dec;15(6):523-8 [18971681.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Dec;1(7):546-53 [19139004.001]
  • [Cites] Breast Cancer Res Treat. 2009 Oct;117(3):561-7 [19153828.001]
  • [Cites] Mol Hum Reprod. 1999 May;5(5):414-20 [10338364.001]
  • (PMID = 20711751.001).
  • [ISSN] 1573-7330
  • [Journal-full-title] Journal of assisted reproduction and genetics
  • [ISO-abbreviation] J. Assist. Reprod. Genet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protective Agents; 094ZI81Y45 / Tamoxifen; 17197F0KYM / afimoxifene; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  • [Other-IDs] NLM/ PMC2995431
  •  go-up   go-down


6. Bajwa RP, Skinner R, Windebank KP, Wariyar UK, Reid MM: Chemotherapy and marrow transplantation for congenital leukaemia. Arch Dis Child Fetal Neonatal Ed; 2001 Jan;84(1):F47-8
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy and marrow transplantation for congenital leukaemia.
  • The optimum approach to congenital leukaemia is unclear.
  • Results of treatment are generally discouraging and palliation is offered to many.
  • The successful treatment of an infant with congenital leukaemia is reported.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation / methods. Leukemia / congenital. Leukemia / therapy
  • [MeSH-minor] Acute Disease. Asparaginase / administration & dosage. Combined Modality Therapy. Cytarabine / administration & dosage. Etoposide / administration & dosage. Female. Humans. Infant, Newborn. Methotrexate / administration & dosage. Mitoxantrone / administration & dosage. Prednisolone / administration & dosage. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Dermatol. 1993 Oct;129(10):1301-6 [8215495.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):931-6 [9508175.001]
  • [Cites] Lancet. 1997 Sep 13;350(9080):767-71 [9297996.001]
  • (PMID = 11124925.001).
  • [ISSN] 1359-2998
  • [Journal-full-title] Archives of disease in childhood. Fetal and neonatal edition
  • [ISO-abbreviation] Arch. Dis. Child. Fetal Neonatal Ed.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 9PHQ9Y1OLM / Prednisolone; BZ114NVM5P / Mitoxantrone; EC 3.5.1.1 / Asparaginase; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ PMC1721195
  •  go-up   go-down


7. Soper BW, Lessard MD, Jude CD, Schuldt AJ, Bunte RM, Barker JE: Successful allogeneic neonatal bone marrow transplantation devoid of myeloablation requires costimulatory blockade. J Immunol; 2003 Sep 15;171(6):3270-7
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful allogeneic neonatal bone marrow transplantation devoid of myeloablation requires costimulatory blockade.
  • Toxic myeloablative pretreatment regimens, graft failure, and graft-vs-host disease complicate the utility of BMT for neonatal treatment.
  • We recently demonstrated high-dose BMT in neonatal animals enables chimeric engraftment without toxic myeloablation.
  • Donor lymphocyte infusion (DLI) re-establishes failing grafts and treats malignant relapse via a graft-vs-leukemia response.
  • In this study, we tested the hypothesis that combining these approaches would allow tolerant allogeneic engraftment devoid of myeloablation in neonatal normal and mutant mice with lysosomal storage disease.
  • DLI-treated mice either maintained long-term tolerance or developed late-onset chronic graft-vs-host disease.
  • This combinatorial approach provides a nontoxic method to establish tolerant allogeneic engraftment for treatment of progressive childhood diseases.
  • [MeSH-minor] Abatacept. Animals. Cells, Cultured. Chimera / immunology. Chronic Disease. Drug Therapy, Combination. Female. Graft Enhancement, Immunologic / methods. Graft vs Host Disease / genetics. Graft vs Host Disease / immunology. H-2 Antigens / genetics. Humans. Immune Tolerance / genetics. Lymphocyte Transfusion. Male. Mice. Mice, Inbred C57BL. Mice, Inbred NOD. Mice, Mutant Strains. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • COS Scholar Universe. author profiles.
  • Jackson Laboratory JAX®Mice Database. culture/stock collections - B6.Cg-Gusb<mps>/BrkJ (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12960357.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA34196; United States / NIDDK NIH HHS / DK / R01 DK41082
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Blocking; 0 / Antibodies, Monoclonal; 0 / H-2 Antigens; 0 / Immunoconjugates; 147205-72-9 / CD40 Ligand; 7D0YB67S97 / Abatacept
  •  go-up   go-down


8. Wong KF, Yuen HL, Siu LL, Pang A, Kwong YL: t(8;16)(p11;p13) predisposes to a transient but potentially recurring neonatal leukemia. Hum Pathol; 2008 Nov;39(11):1702-7
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] t(8;16)(p11;p13) predisposes to a transient but potentially recurring neonatal leukemia.
  • A Chinese girl presented with generalized papular rash and monocytic leukemia 19 days after birth.
  • Spontaneous regression of the leukemia was observed after 2 months, although the t(8;16) translocation persisted cytogenetically.
  • This was followed 7 months later by the development of acute myeloid leukemia with maturation and cytogenetic evolution with extra chromosomes 4 and 8.
  • Molecular study showed that the reciprocal MYST3 and CREBBP gene fusion characteristic of t(8;16) translocation persisted throughout the clinical course, even during spontaneous regression of the neonatal leukemia, and after chemotherapy-induced remission of the subsequent acute myeloid leukemia.
  • The possible role of MYST3 and CREBBP gene fusion in the pathogenesis of the leukemia is discussed.
  • [MeSH-major] Leukemia, Monocytic, Acute / genetics. Leukemia, Myeloid, Acute / genetics. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18657848.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CREBBP protein, human; EC 2.3.1.48 / CREB-Binding Protein; EC 2.3.1.48 / Histone Acetyltransferases; EC 2.3.1.48 / KAT6A protein, human
  •  go-up   go-down


9. Hoopmann M, Rahimi G, Hartlapp I, Eifinger F, Garnier Y, Bald R: [Chemotherapy-induced fetal anemia in maternal acute myelocytic leukemia]. Ultraschall Med; 2008 Aug;29(4):424-7
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemotherapy-induced fetal anemia in maternal acute myelocytic leukemia].
  • This article discusses the management of a pregnancy of a 32-year-old primigravida with acute myelocytic leukemia treated with induction chemotherapy starting in the 20 + 5 week of gestation.
  • The present report describes the interdisciplinary therapeutic management when polychemotherapy during pregnancy is necessary for the mother.
  • Cases of acute leukemia in pregnancy are complicated by severe prenatal risks caused by the hematologic illness and by the immediate beginning of chemotherapy.
  • In the second trimester the pregnancy has to be monitored for the typical risks and complications of chemotherapy.
  • [MeSH-major] Anemia, Neonatal / chemically induced. Antineoplastic Combined Chemotherapy Protocols / toxicity. Leukemia, Myeloid, Acute / drug therapy. Pregnancy Complications, Neoplastic / drug therapy. Ultrasonography, Prenatal
  • [MeSH-minor] Adult. Bone Marrow / drug effects. Cesarean Section. Cooperative Behavior. Female. Follow-Up Studies. Humans. Infant, Newborn. Jaundice, Neonatal / chemically induced. Jaundice, Neonatal / ultrasonography. Patient Care Team. Pregnancy. Pregnancy Trimester, Second

  • Genetic Alliance. consumer health - Acute Myelocytic Leukemia.
  • Genetic Alliance. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17717788.001).
  • [ISSN] 1438-8782
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


10. Udink ten Cate FE, ten Hove CH, Nix WM, de Vries JI, van de Loosdrecht AA, van Elburg RM: Transient neonatal myelosuppression after fetal exposure to maternal chemotherapy. Case report and review of the literature. Neonatology; 2009;95(1):80-5
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transient neonatal myelosuppression after fetal exposure to maternal chemotherapy. Case report and review of the literature.
  • Transient neonatal myelosuppression (TNM) is a rare but potentially life-threatening adverse effect of fetal exposure to maternal chemotherapy during pregnancy.
  • We report a case of TNM in a preterm infant born to a mother diagnosed with acute lymphoblastic leukemia during pregnancy.
  • The mother received chemotherapy during the second and third trimester.
  • Prompt recognition and aggressive treatment of infants at risk for TNM is mandatory.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Bone Marrow / drug effects. Fetus / drug effects. Maternal-Fetal Exchange. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Pregnancy Complications, Neoplastic / drug therapy
  • [MeSH-minor] Adult. Female. Humans. Pregnancy. Pregnancy Outcome. Stem Cell Transplantation. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel.
  • (PMID = 18787341.001).
  • [ISSN] 1661-7819
  • [Journal-full-title] Neonatology
  • [ISO-abbreviation] Neonatology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


11. Chantrain CF, Sauvage D, Brichard B, Dupont S, Poirel HA, Ameye G, De Weer A, Vandenberghe P, Detaille T, Anslot C, de Cléty SC, Vermylen C: Neonatal acute myeloid leukemia in an infant whose mother was exposed to diethylstilboestrol in utero. Pediatr Blood Cancer; 2009 Aug;53(2):220-2
Hazardous Substances Data Bank. DIETHYLSTILBESTROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neonatal acute myeloid leukemia in an infant whose mother was exposed to diethylstilboestrol in utero.
  • We report on an acute myeloid leukemia in a neonate whose mother was exposed to diethylstilboestrol in utero.
  • The newborn presented with leukemia cutis, hemorrhagic skin lesions, hyperleucocytosis and disseminated intravascular coagulation.
  • A bone marrow examination confirmed the diagnosis of acute monocytic leukemia with a t(11;19) MLL-ELL fusion transcript.
  • Chemotherapy was initiated but the child developed a bilateral pulmonary infection that led to fatal respiratory distress.
  • This case shows acute myeloid leukemia and the third pediatric leukemia reported after maternal diethylstilboestrol exposure.
  • [MeSH-major] Diethylstilbestrol / adverse effects. Estrogens, Non-Steroidal / adverse effects. Leukemia, Myeloid, Acute / chemically induced. Prenatal Exposure Delayed Effects / chemically induced
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. In Situ Hybridization, Fluorescence. Infant, Newborn. Infertility, Female / chemically induced. Male. Mothers. Myeloid-Lymphoid Leukemia Protein. Oncogene Proteins, Fusion. Pedigree. Pregnancy. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19405140.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogens, Non-Steroidal; 0 / MLL-ELL fusion protein, human; 0 / Oncogene Proteins, Fusion; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; 731DCA35BT / Diethylstilbestrol
  •  go-up   go-down


12. Askin DF: Neonatal cancer: a clinical perspective. J Obstet Gynecol Neonatal Nurs; 2000 Jul-Aug;29(4):423-31

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neonatal cancer: a clinical perspective.
  • The diagnosis of a neonatal malignancy, while rare, requires complex knowledgeable care from members of the health care team.
  • The neonatal intensive care nurse plays an important role on that team.
  • The types of malignancies found in neonates differ from those in older children, as do the neonate's responses to treatment.
  • A review of the presentation, diagnosis, and management of the more common types of neonatal malignancies provides the context for consideration of the nurse's role in providing specialized care to neonates with cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10929846.001).
  • [ISSN] 0884-2175
  • [Journal-full-title] Journal of obstetric, gynecologic, and neonatal nursing : JOGNN
  • [ISO-abbreviation] J Obstet Gynecol Neonatal Nurs
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 25
  •  go-up   go-down


13. Matsuda K, Sakashita K, Taira C, Tanaka-Yanagisawa M, Yanagisawa R, Shiohara M, Kanegane H, Hasegawa D, Kawasaki K, Endo M, Yajima S, Sasaki S, Kato K, Koike K, Kikuchi A, Ogawa A, Watanabe A, Sotomatsu M, Nonoyama S, Koike K: Quantitative assessment of PTPN11 or RAS mutations at the neonatal period and during the clinical course in patients with juvenile myelomonocytic leukaemia. Br J Haematol; 2010 Feb;148(4):593-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative assessment of PTPN11 or RAS mutations at the neonatal period and during the clinical course in patients with juvenile myelomonocytic leukaemia.
  • To evaluate minimal residual disease (MRD) after chemotherapy and haematopoietic stem cell transplantation in juvenile myelomonocytic leukaemia (JMML), a locked nucleic acid-allele specific quantitative polymerase chain reaction (LNA-AS-qPCR) was developed for 13 patients (four types of PTPN11 mutation and four types of RAS mutation).
  • Non-intensive chemotherapy exerted no substantial reduction of the tumour burden in three patients.
  • Considering the negative correlation between mutant DNA level in neonatal blood spots and age at diagnosis, JMML patients with a larger tumour burden at birth appeared to show earlier onset.
  • [MeSH-major] Genes, ras. Leukemia, Myelomonocytic, Juvenile / genetics. Mutation. Protein Tyrosine Phosphatase, Non-Receptor Type 11 / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19874312.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 3.1.3.48 / PTPN11 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatase, Non-Receptor Type 11
  •  go-up   go-down


14. Aydemir ZA, Ozdemir N, Celik N, Celkan T: [Alcaligenes xylosoxidans bacteremia in a patient with acute lymphoblastic leukemia]. Mikrobiyol Bul; 2009 Jul;43(3):481-5
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Alcaligenes xylosoxidans bacteremia in a patient with acute lymphoblastic leukemia].
  • In this report, a case of A. xylosoxidans bacteremia that developed in a child with acute lymphoblastic leukemia (ALL) was presented.
  • Four-years-old male patient under ALL induction therapy was admitted with symptoms of lethargy, headache, somnolence, and fever (39 degrees C).
  • Cerebrospinal fluid, blood, throat and urine cultures were taken from the patient and empirical treatment with sulbactam cefoperazon and amikacin was initiated.
  • The agent which was non-fermentative, indol and H2S negative, was identified as A. xylosoxidans by API 20 NE (Bio Merieux, France).
  • Since fever continued under the current antibiotic treatment, the therapy was switched to imipenem (90 mg/kg 3x/day) and the patient's condition improved markedly after 24 hours.
  • Following 14 days of imipenem therapy, the patient recovered and discharged from the hospital on routine follow-up.
  • It is important to consider A. xylosoxidans as a possible causative agent particularly in the infections that develop in high risk patients at oncology, dialysis and neonatal intensive care units.
  • [MeSH-major] Alcaligenes / isolation & purification. Bacteremia / microbiology. Gram-Negative Bacterial Infections / microbiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
  • [MeSH-minor] Anti-Bacterial Agents / pharmacology. Anti-Bacterial Agents / therapeutic use. Child, Preschool. Drug Resistance, Multiple, Bacterial. Humans. Imipenem / pharmacology. Imipenem / therapeutic use. Male. Microbial Sensitivity Tests

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19795625.001).
  • [ISSN] 0374-9096
  • [Journal-full-title] Mikrobiyoloji bülteni
  • [ISO-abbreviation] Mikrobiyol Bul
  • [Language] tur
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 71OTZ9ZE0A / Imipenem
  •  go-up   go-down


15. Magalhães IQ, Splendore A, Emerenciano M, Córdoba MS, Córdoba JC, Allemand PA, Ferrari I, Pombo-de-Oliveira MS: Transient neonatal myeloproliferative disorder without Down syndrome and detection of GATA1 mutation. J Pediatr Hematol Oncol; 2005 Jan;27(1):50-2
MedlinePlus Health Information. consumer health - Down Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transient neonatal myeloproliferative disorder without Down syndrome and detection of GATA1 mutation.
  • Transient myeloproliferative disorder is a form of self-limited leukemia that occurs almost exclusively in neonates with Down syndrome.
  • The authors report an unusual case of a newborn without constitutional trisomy 21 who developed undifferentiated leukemia and subsequently achieved clinical and molecular remission without chemotherapy.

  • Genetic Alliance. consumer health - Down Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15654280.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Erythroid-Specific DNA-Binding Factors; 0 / GATA1 Transcription Factor; 0 / GATA1 protein, human; 0 / Transcription Factors
  •  go-up   go-down


16. Xu XJ, Tang YM, Song H, Yang SL, Shi SW, Wei J: Long-term outcome of childhood acute myeloid leukemia in a developing country: experience from a children's hospital in China. Leuk Lymphoma; 2010 Dec;51(12):2262-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of childhood acute myeloid leukemia in a developing country: experience from a children's hospital in China.
  • Data on childhood acute myeloid leukemia (AML) in developing countries are limited.
  • Sixty patients (32.4%) refused chemotherapy and 123 were eligible for protocol evaluation.
  • Thirty-one patients (25.2%) relapsed, but no central nervous system leukemia was observed.
  • Although the cure rate of childhood AML in China was low, the treatment outcome for patients who could adhere to the treatment protocol was satisfactory.
  • [MeSH-major] Developing Countries. Hospitals, Pediatric / statistics & numerical data. Leukemia, Myeloid, Acute / mortality. Leukemia, Myeloid, Acute / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. China. Cohort Studies. Female. Humans. Infant. Male. Survival Analysis. Time Factors. Treatment Outcome


17. Lucas G, Culliford S, Green F, Sidra G, Calvert A, Green A, Harrison P, Harvey J, Allen D, Smillie D, Masurekar A, Marks D, Russell N, Massey E: Recipient-derived HPA-1a antibodies: a cause of prolonged thrombocytopenia after unrelated donor stem cell transplantation. Transfusion; 2010 Feb;50(2):334-9
MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Patients with human platelet antigen (HPA) specific antibodies in cases of neonatal alloimmune thrombocytopenia and platelet (PLT) refractoriness derive clinical benefit from the use of HPA-selected PLTs.
  • STUDY DESIGN AND METHODS: This study describes three patients with underlying diagnoses of acute myeloid leukemia, chronic lymphocytic leukemia, and myelodysplasia, respectively, who underwent allogeneic bone marrow transplantation (BMT) with unrelated donors matched at the HLA-A, B, C, Dr, and DQ loci but who failed to achieve an adequate PLT count.
  • RESULTS: In two patients, anti-HPA-1a was detected post-BMT and in the third patient, anti-HPA-1a was detected during pre-BMT chemotherapy.
  • [MeSH-minor] Acute Disease. Anemia, Refractory / drug therapy. Anemia, Refractory / immunology. Anemia, Refractory / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Fatal Outcome. Female. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / immunology. Leukemia, Lymphocytic, Chronic, B-Cell / surgery. Leukemia, Myeloid / drug therapy. Leukemia, Myeloid / immunology. Leukemia, Myeloid / surgery. Male. Middle Aged. Platelet Transfusion

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19874563.001).
  • [ISSN] 1537-2995
  • [Journal-full-title] Transfusion
  • [ISO-abbreviation] Transfusion
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 1a alloantigen, human; 0 / Antigens, Human Platelet; 0 / Isoantibodies
  •  go-up   go-down


18. Kucheria K, Jobanputra V, Talwar R, Ahmad ME, Dada R, Sivakumaran TA: Human molecular cytogenetics: diagnosis, prognosis, and disease management. Teratog Carcinog Mutagen; 2003;Suppl 1:225-33

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To conclude, FISH adds to the diagnostic utility of routine cytogenetics and its use on interphase nuclei overcomes the difficulty of conventional cytogenetics, thereby reducing the time between sampling and diagnosis to 24 hr.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Bone Marrow Transplantation. Cell Line. Chromosome Painting. Female. Genetic Testing. Humans. In Situ Hybridization, Fluorescence. Infant, Newborn. Interferon-alpha / therapeutic use. Leukemia, Myeloid / diagnosis. Leukemia, Myeloid / drug therapy. Leukemia, Myeloid / genetics. Leukemia, Myeloid / therapy. Male. Neonatal Screening. Pregnancy. Pregnancy Complications / diagnosis. Prenatal Diagnosis. Prognosis. Sex Chromosome Disorders / diagnosis. Sex Chromosome Disorders / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 12616613.001).
  • [ISSN] 0270-3211
  • [Journal-full-title] Teratogenesis, carcinogenesis, and mutagenesis
  • [ISO-abbreviation] Teratog., Carcinog. Mutagen.
  • [Language] eng
  • [Publication-type] Congresses; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha
  •  go-up   go-down


19. Zhang C, Liang MY, Wang SM: [Clinical analysis of bicytopenia and pancytopenia during pregnancy]. Zhonghua Fu Chan Ke Za Zhi; 2009 Jul;44(7):488-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Retrospective chart review was conducted on 24 pregnancies who were found bicytopenia or pancytopenia during pregnancy for the first time.
  • RESULTS: According to the clinical data and laboratory findings, the latter including complete blood cell count, reticulocyte count, peripheral smear, serum folate and vitamin B12 level, autoimmune antibody screening, bone marrow smear and biopsy, thirteen patients were diagnosed as having chronic aplastic anemia (CAA), six as having myelodysplastic syndromes (MDS), two as having megaloblastic anemia (MA), one as having paroxysmal nocturnal hemoglobinuria (PNH), one as having Evan's syndrome and one as having acute leukemia.
  • The delivery ages of the 21 patients were term or nearly term with all good neonatal outcomes.
  • The patient with acute leukemia died of recurrence six months postpartum.
  • Of the 6 patients with MDS, one achieved partial remission, four no remission, and one transformed into acute monocytic leukemia, then refused chemotherapy and was lost follow-up.
  • [MeSH-major] Anemia, Aplastic / therapy. Blood Transfusion. Pancytopenia / therapy. Pregnancy Complications, Hematologic / diagnosis. Pregnancy Complications, Hematologic / therapy. Pregnancy Outcome
  • [MeSH-minor] Adult. Biopsy, Needle. Bone Marrow / pathology. Bone Marrow Examination. Female. Folic Acid / therapeutic use. Follow-Up Studies. Humans. Myelodysplastic Syndromes / diagnosis. Myelodysplastic Syndromes / pathology. Myelodysplastic Syndromes / therapy. Pregnancy. Prognosis. Retrospective Studies. Young Adult


20. Friedman JS, Rebel VI, Derby R, Bell K, Huang TT, Kuypers FA, Epstein CJ, Burakoff SJ: Absence of mitochondrial superoxide dismutase results in a murine hemolytic anemia responsive to therapy with a catalytic antioxidant. J Exp Med; 2001 Apr 16;193(8):925-34
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absence of mitochondrial superoxide dismutase results in a murine hemolytic anemia responsive to therapy with a catalytic antioxidant.
  • Manganese superoxide dismutase 2 (SOD2) is a critical component of the mitochondrial pathway for detoxification of O2(-), and targeted disruption of this locus leads to embryonic or neonatal lethality in mice.
  • To follow the effects of SOD2 deficiency in cells over a longer time course, we created hematopoietic chimeras in which all blood cells are derived from fetal liver stem cells of Sod2 knockout, heterozygous, or wild-type littermates.
  • Treatment of anemic animals with Euk-8, a catalytic antioxidant with both SOD and catalase activities, significantly corrected this oxidative stress-induced condition.
  • Such therapy may prove useful in treatment of human disorders such as sideroblastic anemia, which SOD2 deficiency most closely resembles.

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1994 Jun 15;83(12):3758-79 [7911343.001]
  • [Cites] Neuropharmacology. 1994 Jul;33(7):929-34 [7969813.001]
  • [Cites] Biochem Med Metab Biol. 1994 Aug;52(2):120-7 [7993658.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6264-8 [7603981.001]
  • [Cites] J Pharmacol Exp Ther. 1995 Nov;275(2):798-806 [7473169.001]
  • [Cites] Nat Genet. 1995 Dec;11(4):376-81 [7493016.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2312-6 [8637869.001]
  • [Cites] Science. 1996 Jul 5;273(5271):59-63 [8658196.001]
  • [Cites] J Biochem. 1996 Apr;119(4):768-74 [8743580.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9782-7 [8790408.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 1996 Sep;51(5):B337-45 [8808982.001]
  • [Cites] Transplantation. 1996 Dec 15;62(11):1664-6 [8970624.001]
  • [Cites] Shock. 1997 Aug;8(2):108-14 [9261900.001]
  • [Cites] Blood. 1997 Dec 15;90(12):4961-72 [9389715.001]
  • [Cites] J Pharmacol Exp Ther. 1998 Jan;284(1):215-21 [9435181.001]
  • [Cites] Nat Genet. 1998 Feb;18(2):159-63 [9462746.001]
  • [Cites] Nat Genet. 1998 Jun;19(2):171-4 [9620775.001]
  • [Cites] Nature. 1998 Aug 13;394(6694):694-7 [9716135.001]
  • [Cites] J Biol Chem. 1998 Oct 23;273(43):28510-5 [9774481.001]
  • [Cites] Science. 1998 Oct 30;282(5390):943-6 [9794765.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 2;96(3):846-51 [9927656.001]
  • [Cites] Arch Biochem Biophys. 1999 Mar 1;363(1):91-7 [10049502.001]
  • [Cites] Hum Mol Genet. 1999 May;8(5):743-9 [10196363.001]
  • [Cites] FASEB J. 1999 Aug;13(11):1385-93 [10428762.001]
  • [Cites] Nature. 1999 Nov 18;402(6759):309-13 [10580504.001]
  • [Cites] Ann N Y Acad Sci. 1999;893:95-112 [10672232.001]
  • [Cites] Science. 2000 Sep 1;289(5484):1567-9 [10968795.001]
  • [Cites] J Biol Chem. 1973 Jul 10;248(13):4793-6 [4578091.001]
  • [Cites] Nouv Rev Fr Hematol. 1975 Nov-Dec;15(6):637-48 [133333.001]
  • [Cites] J Pediatr. 1979 Dec;95(6):976-84 [501502.001]
  • [Cites] Blood. 1987 Mar;69(3):899-907 [3493045.001]
  • [Cites] Lancet. 1989 Apr 22;1(8643):902-3 [2564980.001]
  • [Cites] J Lab Clin Med. 1990 Oct;116(4):535-45 [2212862.001]
  • [Cites] Blood Rev. 1990 Sep;4(3):141-7 [2245249.001]
  • [Cites] Ann Hematol. 1993 Aug;67(2):81-7 [8347734.001]
  • [Cites] Biochem Biophys Res Commun. 1993 Oct 15;196(1):7-11 [8216337.001]
  • [Cites] Leukemia. 1993 Dec;7(12):2069-76 [8255108.001]
  • (PMID = 11304553.001).
  • [ISSN] 0022-1007
  • [Journal-full-title] The Journal of experimental medicine
  • [ISO-abbreviation] J. Exp. Med.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK32094; United States / NIDDK NIH HHS / DK / P01 DK032094; United States / NHLBI NIH HHS / HL / HL03748; United States / NCI NIH HHS / CA / P01CA39542; United States / NIA NIH HHS / AG / AG14694; United States / NCI NIH HHS / CA / P01 CA039542; United States / NIA NIH HHS / AG / AG16998
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Ethylenediamines; 0 / Free Radical Scavengers; 0 / Isoenzymes; 0 / Organometallic Compounds; 53177-12-1 / N,N'-bis(salicylideneamino)ethane-manganese(II); EC 1.15.1.1 / Superoxide Dismutase
  • [Other-IDs] NLM/ PMC2193409
  •  go-up   go-down


21. Sutor AH, Chan AK, Massicotte P: Low-molecular-weight heparin in pediatric patients. Semin Thromb Hemost; 2004 Feb;30 Suppl 1:31-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There are several predisposing risk factors for newborns such as small vessels, high hematocrit, and a unique neonatal hemostatic system.
  • The serious sequelae of TEs (mortality, and short- and long-term morbidity) require therapeutic intervention.
  • Unfractionated heparin (UFH) has the following disadvantages: age-dependent unpredictable pharmacokinetics, the need for intravenous access for therapy and monitoring, delays in achieving therapeutic ranges, bleeding risk, the risk of heparin-induced thrombocytopenia, and osteoporosis with long-term use.
  • Oral anticoagulants, in addition to some of these disadvantages, show considerable variation by diet (especially if there is a change from breast to bottle feeding), medication, and intercurrent illness.
  • If dosages are calculated according to body weight, infants < 3 months (or < 5 kg) need approximately 50% more LMWH than older children or adults to reach prophylactic or therapeutic anti-factor Xa levels.
  • Further studies are necessary to address the following: the importance of risk factors, the necessity of screening for hereditary thrombophilia, the efficacy and safety of treatment, and side effects and duration of treatment.
  • Retrospective surveys in children treated for acute lymphoblastic leukemia with corticosteroids and asparaginase revealed clinically symptomatic TE in only 2 to 12% of patients.
  • The objectives of this article are to update the present knowledge on TEs in children, including incidence, predominant age groups, risk factors, diagnosis, and indications for prophylaxis and therapy; and to discuss the use of low-molecular-weight heparin (LMWH) in children.
  • [MeSH-major] Heparin, Low-Molecular-Weight / therapeutic use. Thromboembolism / drug therapy
  • [MeSH-minor] Child. Female. Humans. Practice Guidelines as Topic. Pregnancy. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15085464.001).
  • [ISSN] 0094-6176
  • [Journal-full-title] Seminars in thrombosis and hemostasis
  • [ISO-abbreviation] Semin. Thromb. Hemost.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Heparin, Low-Molecular-Weight
  • [Number-of-references] 56
  •  go-up   go-down


22. Holtan SG, Creedon DJ, Haluska P, Markovic SN: Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents. Mayo Clin Proc; 2009 Nov;84(11):985-1000
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents.
  • In addition to the shared capacity for invading through normal tissues, both cancer cells and cells of the developing placenta create a microenvironment supportive of both immunologic privilege and angiogenesis.
  • Systemic alterations in immunity are also detectable, particularly with respect to a helper T cell type 2 polarization evident in advanced cancers and midtrimester pregnancy.
  • The knowledge gained from analyzing similarities and differences between the physiologic state of pregnancy and the pathologic state of cancer could lead to identification of new potential targets for cancer therapeutic agents.
  • [MeSH-major] Antineoplastic Agents / immunology. Cell Transformation, Neoplastic / immunology. Neoplasm Invasiveness / immunology. Neoplasms / drug therapy. Neoplasms / immunology. Pregnancy / immunology
  • [MeSH-minor] Academic Medical Centers. Cell Movement / immunology. Cell Proliferation. Drug Delivery Systems. Female. Humans. Immune System Phenomena / immunology. Immune System Phenomena / physiology. Immunologic Factors. Minnesota. Neovascularization, Pathologic / immunology. Pregnancy Trimester, Third

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biol Reprod. 2000 Apr;62(4):959-68 [10727265.001]
  • [Cites] Am J Pathol. 2000 Jul;157(1):159-69 [10880386.001]
  • [Cites] Am J Obstet Gynecol. 2000 Sep;183(3):682-8 [10992193.001]
  • [Cites] Mol Hum Reprod. 2000 Oct;6(10):943-50 [11006324.001]
  • [Cites] Curr Biol. 2001 May 1;11(9):691-6 [11369232.001]
  • [Cites] Obstet Gynecol. 2001 Jun;97(6):965-70 [11384704.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):369-76 [11466692.001]
  • [Cites] J Pathol. 2003 May;200(1):47-52 [12692840.001]
  • [Cites] Front Biosci. 2003 May 1;8:d714-22 [12700030.001]
  • [Cites] Biol Reprod. 2003 May;68(5):1496-504 [12606489.001]
  • [Cites] ScientificWorldJournal. 2002 Feb 12;2:421-3 [12806026.001]
  • [Cites] J Leukoc Biol. 2003 Oct;74(4):514-22 [12960246.001]
  • [Cites] J Exp Med. 2003 Oct 20;198(8):1201-12 [14568979.001]
  • [Cites] Hum Immunol. 2003 Nov;64(11):1064-72 [14602237.001]
  • [Cites] Hum Immunol. 2003 Nov;64(11):1093-101 [14602240.001]
  • [Cites] Am J Reprod Immunol. 2003 Sep;50(3):187-95 [14629022.001]
  • [Cites] Semin Cancer Biol. 2003 Oct;13(5):371-7 [14708717.001]
  • [Cites] Semin Cancer Biol. 2003 Oct;13(5):379-85 [14708718.001]
  • [Cites] Cancer Cell. 2004 Mar;5(3):231-9 [15050915.001]
  • [Cites] Clin Exp Immunol. 2004 May;136(2):373-8 [15086404.001]
  • [Cites] Mol Hum Reprod. 2004 May;10(5):347-53 [14997000.001]
  • [Cites] Immunology. 2004 May;112(1):38-43 [15096182.001]
  • [Cites] Reprod Biol Endocrinol. 2004 Mar 25;2:15 [15043753.001]
  • [Cites] J Natl Cancer Inst. 2004 Oct 6;96(19):1473-7 [15467037.001]
  • [Cites] Tsitologiia. 2004;46(7):640-8 [15473375.001]
  • [Cites] Proc R Soc Med. 1968 Nov;61(11 Pt 2):1213-6 [4178362.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Dec;78(12):7327-30 [6174971.001]
  • [Cites] Int J Cancer. 1985 Nov 15;36(5):541-4 [3876999.001]
  • [Cites] J Immunol. 1987 Apr 15;138(8):2481-7 [3104468.001]
  • [Cites] J Reprod Immunol. 1988 Dec;14(3):291-302 [3225818.001]
  • [Cites] Lancet. 1990 Jul 28;336(8709):197-200 [1973769.001]
  • [Cites] J Clin Invest. 1990 Nov;86(5):1503-10 [2243127.001]
  • [Cites] FASEB J. 1992 Mar;6(6):2344-8 [1544544.001]
  • [Cites] Science. 1994 Dec 23;266(5193):2011-5 [7605428.001]
  • [Cites] Hum Immunol. 1994 Sep;41(1):79-86 [7836069.001]
  • [Cites] J Immunol. 1995 Apr 15;154(8):3771-8 [7706718.001]
  • [Cites] Hum Pathol. 1995 Nov;26(11):1201-6 [7590693.001]
  • [Cites] Obstet Gynecol. 1996 Jul;88(1):47-50 [8684760.001]
  • [Cites] Proc Assoc Am Physicians. 1997 Jan;109(1):1-9 [9010911.001]
  • [Cites] Acta Anat (Basel). 1996;156(3):202-16 [9124037.001]
  • [Cites] J Clin Invest. 1997 May 1;99(9):2139-51 [9151786.001]
  • [Cites] Placenta. 1997 Jul-Aug;18(5-6):433-9 [9250706.001]
  • [Cites] Lancet. 1997 Aug 16;350(9076):485-7 [9274585.001]
  • [Cites] Am J Reprod Immunol. 1997 Sep;38(3):189-96 [9325491.001]
  • [Cites] Placenta. 1997 Nov;18(8):657-65 [9364601.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Dec 18;241(2):498-503 [9425299.001]
  • [Cites] Mol Biol Cell. 1998 Apr;9(4):795-807 [9529378.001]
  • [Cites] Diabetes Care. 1998 Aug;21 Suppl 2:B60-9 [9704229.001]
  • [Cites] Mediators Inflamm. 1998;7(2):69-72 [9836491.001]
  • [Cites] J Immunol. 1999 May 15;162(10):6053-9 [10229846.001]
  • [Cites] Nat Med. 1999 Jun;5(6):669-76 [10371506.001]
  • [Cites] J Reprod Immunol. 1999 Jul;43(2):111-25 [10479048.001]
  • [Cites] Cancer Metastasis Rev. 1999;18(1):65-73 [10505546.001]
  • [Cites] Nat Rev Drug Discov. 2004 Dec;3(12):1011-22 [15573100.001]
  • [Cites] Oncol Rep. 2005 Jan;13(1):37-44 [15583799.001]
  • [Cites] Gynecol Oncol. 2005 Jan;96(1):42-7 [15589578.001]
  • [Cites] Nat Rev Cancer. 2005 Jan;5(1):29-41 [15630413.001]
  • [Cites] J Reprod Immunol. 2005 Apr;65(2):111-20 [15811516.001]
  • [Cites] Placenta. 2005 Apr;26 Suppl A:S21-30 [15837062.001]
  • [Cites] Placenta. 2005 Apr;26 Suppl A:S63-9 [15837070.001]
  • [Cites] Clin Cancer Res. 2007 Jun 1;13(11):3333-8 [17545540.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5594-9 [17575122.001]
  • [Cites] Int J Gynaecol Obstet. 2007 Jul;98(1):48-53 [17490670.001]
  • [Cites] J Physiol. 2007 Jul 1;582(Pt 1):449-59 [17463046.001]
  • [Cites] Cancer Cell. 2007 Jul;12(1):9-22 [17613433.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6433-41 [17616704.001]
  • [Cites] Scand J Immunol. 2007 Aug-Sep;66(2-3):143-58 [17635792.001]
  • [Cites] Expert Opin Ther Targets. 2007 Aug;11(8):1005-9 [17665973.001]
  • [Cites] Virchows Arch. 2007 Feb;450(2):195-202 [17149611.001]
  • [Cites] J Reprod Immunol. 2007 Oct;75(2):71-81 [17686527.001]
  • [Cites] Ann Surg Oncol. 2007 Oct;14(10):2721-9 [17564748.001]
  • [Cites] Nat Clin Pract Oncol. 2007 Oct;4(10):591-602 [17898809.001]
  • [Cites] Clin Cancer Res. 2007 Oct 1;13(19):5834-40 [17908976.001]
  • [Cites] Int J Oncol. 2007 Nov;31(5):1111-7 [17912437.001]
  • [Cites] Nat Rev Cancer. 2007 Nov;7(11):880-7 [17957190.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7234-42 [16243793.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7297-303 [16243800.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8136-9 [16258121.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):16078-83 [16249345.001]
  • [Cites] Cancer Sci. 2005 Nov;96(11):791-800 [16271073.001]
  • [Cites] Cancer Biol Ther. 2005 Sep;4(9):1018-29 [16251803.001]
  • [Cites] Reprod Biol Endocrinol. 2005;3:56 [16236179.001]
  • [Cites] J Immunol. 2006 Jan 1;176(1):157-64 [16365406.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Jan;3(1):24-40 [16407877.001]
  • [Cites] J Immunol. 2006 Feb 1;176(3):1534-42 [16424182.001]
  • [Cites] Curr Opin Immunol. 2006 Apr;18(2):220-5 [16460921.001]
  • [Cites] Am J Pathol. 2006 Apr;168(4):1134-47 [16565489.001]
  • [Cites] J Immunol. 2006 Apr 15;176(8):4716-29 [16585565.001]
  • [Cites] Neoplasia. 2006 Mar;8(3):223-30 [16611416.001]
  • [Cites] Cancer Immunol Immunother. 2006 Aug;55(8):987-95 [16485129.001]
  • [Cites] Tumour Biol. 2006;27(4):187-94 [16651853.001]
  • [Cites] Nat Rev Immunol. 2006 Jun;6(6):433-46 [16724098.001]
  • [Cites] Egypt J Immunol. 2005;12(1):57-64 [16734140.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 2006 Mar-Apr;42(3-4):89-95 [16759154.001]
  • [Cites] Mol Immunol. 2006 Jul;43(14):2151-60 [16490253.001]
  • [Cites] Blood. 2006 Jul 1;108(1):228-37 [16522817.001]
  • [Cites] Virchows Arch. 2006 Jul;449(1):31-9 [16541284.001]
  • [Cites] J Reprod Immunol. 2006 Aug;71(1):75-86 [16616377.001]
  • [Cites] Blood. 2006 Aug 1;108(3):804-11 [16861339.001]
  • [Cites] Am J Obstet Gynecol. 2006 Aug;195(2):394.e1-24 [16890549.001]
  • [Cites] Cancer Biol Ther. 2006 Jul;5(7):860-6 [16861916.001]
  • [Cites] FASEB J. 2006 Sep;20(11):1921-3 [16877523.001]
  • [Cites] Nat Med. 2006 Sep;12(9):1065-74 [16892062.001]
  • [Cites] Gynecol Oncol. 2006 Oct;103(1):25-30 [16530254.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6144-52 [17062691.001]
  • [Cites] Leuk Lymphoma. 2006 Sep;47(9):1941-8 [17065009.001]
  • [Cites] J Reprod Immunol. 2006 Dec;72(1-2):33-45 [16843534.001]
  • [Cites] Blood. 2006 Dec 15;108(13):4194-7 [16946299.001]
  • [Cites] Am J Reprod Immunol. 2007 Jan;57(1):55-66 [17156192.001]
  • [Cites] J Mol Med (Berl). 2007 Jan;85(1):15-22 [17106733.001]
  • [Cites] PLoS Comput Biol. 2006 Dec 29;2(12):e180 [17196035.001]
  • [Cites] Mol Hum Reprod. 2007 Feb;13(2):123-33 [17121749.001]
  • [Cites] Curr Opin Genet Dev. 2007 Feb;17(1):45-51 [17208432.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9265-70 [11459932.001]
  • [Cites] Prostate. 2001 Sep 15;48(4):254-64 [11536305.001]
  • [Cites] Am J Pathol. 2001 Sep;159(3):817-24 [11549573.001]
  • [Cites] Placenta. 2001 Sep-Oct;22(8-9):663-72 [11597186.001]
  • [Cites] J Immunol. 2002 May 1;168(9):4772-80 [11971028.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2530-6 [12011132.001]
  • [Cites] Endocrinology. 2002 Jun;143(6):2119-38 [12021176.001]
  • [Cites] Nat Rev Immunol. 2002 Aug;2(8):569-79 [12154376.001]
  • [Cites] Nat Rev Immunol. 2002 Sep;2(9):656-63 [12209134.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6706-11 [12438270.001]
  • [Cites] Eur J Immunol. 2003 Jan;33(1):125-34 [12594841.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1454-6 [17456752.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1763-80 [17456780.001]
  • [Cites] J Clin Oncol. 2007 May 1;25(13):1732-40 [17389336.001]
  • [Cites] Life Sci. 2007 Oct 13;81(17-18):1323-31 [17936851.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10556-63 [17975000.001]
  • [Cites] Cell. 2007 Nov 2;131(3):463-75 [17981115.001]
  • [Cites] Obstet Gynecol. 2007 Nov;110(5):1137-45 [17978130.001]
  • [Cites] Oncol Rep. 2007 Dec;18(6):1463-8 [17982631.001]
  • [Cites] Semin Cancer Biol. 2007 Dec;17(6):444-50 [17707652.001]
  • [Cites] Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6735-42 [18006775.001]
  • [Cites] Am J Clin Pathol. 2007 Dec;128(6):1002-9 [18024326.001]
  • [Cites] J Reprod Immunol. 2007 Dec;76(1-2):61-7 [17482271.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Jan 11;365(2):279-84 [17991428.001]
  • [Cites] Food Chem Toxicol. 2008 Jan;46(1):203-11 [17868966.001]
  • [Cites] Recent Results Cancer Res. 2008;177:137-50 [18084956.001]
  • [Cites] Am J Reprod Immunol. 2008 Jan;59(1):75-83 [18154598.001]
  • [Cites] Immunol Lett. 2008 Jan 15;115(1):21-32 [18055021.001]
  • [Cites] J Immunol. 2008 Jan 15;180(2):699-705 [18178807.001]
  • [Cites] J Reprod Immunol. 2008 Jan;77(1):14-22 [17561268.001]
  • [Cites] Expert Opin Ther Targets. 2008 Feb;12(2):209-22 [18208369.001]
  • [Cites] Development. 2008 Feb;135(4):717-27 [18199579.001]
  • [Cites] J Cell Biochem. 2008 Feb 15;103(3):719-29 [17661346.001]
  • [Cites] Cancer. 2008 Feb 15;112(4):863-75 [18203207.001]
  • [Cites] J Matern Fetal Neonatal Med. 2007 Dec;20(12):867-78 [17853188.001]
  • [Cites] Am J Reprod Immunol. 2008 Mar;59(3):201-5 [18275513.001]
  • [Cites] Cancer Res. 2008 Feb 15;68(4):1213-20 [18281498.001]
  • [Cites] Curr Opin Oncol. 2008 Mar;20(2):183-9 [18300768.001]
  • [Cites] Blood. 2008 Mar 15;111(6):3108-15 [18187664.001]
  • [Cites] Mol Interv. 2008 Feb;8(1):22-7 [18332481.001]
  • [Cites] Reprod Biol Endocrinol. 2006;4 Suppl 1:S10 [17118165.001]
  • [Cites] Immunol Rev. 2008 Apr;222:206-21 [18364004.001]
  • [Cites] Am J Med. 2008 Apr;121(4):302-9 [18374689.001]
  • [Cites] Curr Oncol Rep. 2008 Mar;10(2):130-6 [18377826.001]
  • [Cites] Cancer Biol Ther. 2008 Jan;7(1):76-80 [18347423.001]
  • [Cites] PLoS One. 2008;3(4):e2078 [18446208.001]
  • [Cites] Cell Physiol Biochem. 2008;21(5-6):463-72 [18453754.001]
  • [Cites] Nature. 1998 Dec 10;396(6711):580-4 [9859993.001]
  • [Cites] Blood. 1999 Mar 15;93(6):2033-7 [10068676.001]
  • [Cites] Exp Cell Res. 1999 Apr 10;248(1):30-43 [10094811.001]
  • [Cites] Dev Cell. 2008 Jun;14(6):818-29 [18539112.001]
  • [Cites] Am J Physiol Cell Physiol. 2008 Jun;294(6):C1313-22 [18400990.001]
  • [Cites] Hum Reprod Update. 2008 Jul-Aug;14(4):335-44 [18424427.001]
  • [Cites] J Exp Med. 2008 Jun 9;205(6):1261-8 [18490490.001]
  • [Cites] Vaccine. 2008 Jun 19;26(26):3252-60 [18479788.001]
  • [Cites] Clin Cancer Res. 2008 Jul 1;14(13):4241-9 [18594006.001]
  • [Cites] J Clin Oncol. 2008 Jul 1;26(19):3196-203 [18474873.001]
  • [Cites] Mayo Clin Proc. 2008 Jul;83(7):825-46 [18613999.001]
  • [Cites] Mol Hum Reprod. 2008 Jul;14(7):413-21 [18524812.001]
  • [Cites] Hum Reprod. 2008 Aug;23(8):1733-41 [18487214.001]
  • [Cites] Cancer Immunol Immunother. 2008 Jul;57(7):987-96 [18060403.001]
  • [Cites] Gynecol Oncol. 2008 Aug;110(2):216-21 [18533240.001]
  • [Cites] Nat Rev Cancer. 2008 Aug;8(8):618-31 [18633355.001]
  • [Cites] Cancer Lett. 2008 Sep 18;268(2):233-43 [18499341.001]
  • [Cites] Blood. 2005 Aug 1;106(3):946-55 [15855273.001]
  • [Cites] Cell Stress Chaperones. 2005 Summer;10(2):86-103 [16038406.001]
  • [Cites] BMC Cancer. 2005;5:66 [15982419.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5920-7 [16115934.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Sep;90(9):5407-13 [15956076.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8350-8 [16166312.001]
  • [Cites] Mini Rev Med Chem. 2005 Sep;5(9):805-24 [16178723.001]
  • [Cites] Annu Rev Cell Dev Biol. 2005;21:695-718 [16212512.001]
  • [Cites] J Reprod Immunol. 2005 Oct;67(1-2):35-50 [16111767.001]
  • [Cites] J Reprod Immunol. 2007 Jun;74(1-2):34-45 [17321596.001]
  • [Cites] Med Chem. 2007 May;3(3):233-9 [17504194.001]
  • [Cites] J Reprod Immunol. 2008 Oct;79(1):50-7 [18550178.001]
  • [Cites] Clin Cancer Res. 2008 Nov 1;14(21):6735-41 [18980965.001]
  • [Cites] Clin Immunol. 2008 Dec;129(3):401-12 [18805741.001]
  • [Cites] Oncogene. 2008 Nov 20;27(54):6866-74 [18820708.001]
  • [Cites] Am J Pathol. 2008 Dec;173(6):1839-52 [18988806.001]
  • [Cites] Drug Resist Updat. 2008 Dec;11(6):219-30 [18948057.001]
  • [Cites] J Exp Med. 2008 Nov 24;205(12):2763-79 [19001139.001]
  • [Cites] Nat Rev Cancer. 2008 Dec;8(12):915-28 [19029956.001]
  • [Cites] J Clin Invest. 2008 Dec;118(12):3954-65 [19033665.001]
  • [Cites] Cytokine Growth Factor Rev. 2008 Oct-Dec;19(5-6):333-45 [18952487.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2008 Dec;13(4):471-83 [19023648.001]
  • [Cites] Vaccine. 2009 Jan 1;27(1):107-15 [18977262.001]
  • [Cites] J Theor Biol. 2009 Jan 7;256(1):65-75 [18930739.001]
  • [Cites] Reprod Sci. 2008 Nov;15(9):866-77 [19050320.001]
  • [Cites] Med Hypotheses. 2008 Nov;71(5):802-4 [18691831.001]
  • [Cites] Hum Reprod. 2009 Jan;24(1):166-75 [18824472.001]
  • [Cites] J Med Chem. 2008 Dec 25;51(24):8109-14 [19053747.001]
  • [Cites] J Thromb Haemost. 2009 Jan;7(1):21-33 [18983480.001]
  • [Cites] Placenta. 2009 Jan;30(1):79-87 [19010534.001]
  • [Cites] Int J Cancer. 2009 Mar 1;124(5):1054-9 [19065666.001]
  • [Cites] J Cell Physiol. 2009 Mar;218(3):512-21 [19040205.001]
  • [Cites] J Leukoc Biol. 2009 Jan;85(1):4-19 [18784344.001]
  • [Cites] Am J Obstet Gynecol. 2009 Jan;200(1):104.e1-11 [19121663.001]
  • [Cites] J Nutr Biochem. 2009 Feb;20(2):87-95 [18495463.001]
  • [Cites] Mol Cancer Ther. 2009 Jan;8(1):1-9 [19139107.001]
  • [Cites] Biochem Biophys Res Commun. 2009 Feb 6;379(2):445-50 [19116140.001]
  • [Cites] Am J Pathol. 2009 Feb;174(2):630-7 [19147820.001]
  • [Cites] Pathophysiol Haemost Thromb. 2008;36(3-4):177-83 [19176990.001]
  • [Cites] Cancer Immunol Immunother. 2009 Apr;58(4):589-601 [18791715.001]
  • [Cites] Mol Cancer Ther. 2009 Feb;8(2):324-32 [19174555.001]
  • [Cites] Oncol Rep. 2009 Mar;21(3):761-7 [19212637.001]
  • [Cites] Transpl Immunol. 2009 Mar;20(4):229-31 [19038339.001]
  • [Cites] Leuk Res. 2009 Apr;33(4):518-24 [18823661.001]
  • [Cites] PLoS One. 2009;4(2):e4622 [19247450.001]
  • [Cites] Clin Cancer Res. 2009 Mar 1;15(5):1612-22 [19223496.001]
  • [Cites] Acta Biochim Biophys Sin (Shanghai). 2009 Mar;41(3):223-30 [19280061.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7668-77 [16885368.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7766-74 [16885380.001]
  • [Cites] J Immunol. 2006 Aug 15;177(4):2391-402 [16888001.001]
  • [Cites] Blood. 2009 Apr 2;113(14):3139-46 [19171876.001]
  • [Cites] Clin Immunol. 2009 Apr;131(1):109-18 [19153062.001]
  • [Cites] Blood. 2009 May 7;113(19):4637-45 [19234140.001]
  • [Cites] Exp Mol Pathol. 2009 Jun;86(3):180-5 [19186177.001]
  • [Cites] Cancer Lett. 2008 Dec 8;272(1):148-59 [18694621.001]
  • [Cites] Hum Immunol. 2008 Apr-May;69(4-5):241-9 [18486758.001]
  • [Cites] J Cell Mol Med. 2008 Jun;12(3):889-98 [18494931.001]
  • [Cites] Lung Cancer. 2008 Jun;60(3):426-33 [18215438.001]
  • [Cites] Clin Cancer Res. 2009 Mar 15;15(6):1931-9 [19240164.001]
  • [Cites] Clin Cancer Res. 2009 Mar 15;15(6):2031-8 [19276268.001]
  • [Cites] Anticancer Res. 2009 Jan;29(1):403-10 [19331179.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):709s-715s [17255298.001]
  • [Cites] Endocrinology. 2007 Mar;148(3):1059-79 [17170095.001]
  • [Cites] Hum Reprod Update. 2007 Mar-Apr;13(2):121-41 [17068222.001]
  • [Cites] Leukemia. 2007 Mar;21(3):566-8 [17252007.001]
  • [Cites] Reprod Biol Endocrinol. 2007;5:6 [17288592.001]
  • [Cites] Growth Horm IGF Res. 2007 Feb;17(1):10-8 [17218136.001]
  • [Cites] Mod Pathol. 2007 Mar;20(3):375-83 [17277760.001]
  • [Cites] EMBO J. 2007 Mar 7;26(5):1423-33 [17318190.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3378-83 [17360654.001]
  • [Cites] Adv Cancer Res. 2007;97:203-24 [17419947.001]
  • [Cites] Mol Cancer Ther. 2007 Apr;6(4):1357-67 [17431114.001]
  • [Cites] Clin Cancer Res. 2008 Aug 15;14(16):5013-21 [18698019.001]
  • [Cites] Exp Hematol. 2008 Sep;36(9):1073-7 [18508187.001]
  • [Cites] Tissue Antigens. 2008 Aug;72(2):137-48 [18721274.001]
  • [Cites] Cell Biol Int. 2008 Sep;32(9):1031-43 [18550395.001]
  • [Cites] Trends Immunol. 2008 Oct;29(10):464-8 [18775673.001]
  • [Cites] Cancer Lett. 2008 Nov 8;270(2):181-90 [18522865.001]
  • [Cites] APMIS. 2008 Jul-Aug;116(7-8):638-47 [18834408.001]
  • [Cites] Dermatology. 2008;217(3):281-3 [18688170.001]
  • [Cites] Oncogene. 2008 Oct 6;27(45):5869-85 [18836468.001]
  • [Cites] J Natl Cancer Inst. 2008 Oct 15;100(20):1464-76 [18840818.001]
  • [Cites] Cancer Res. 2008 Oct 15;68(20):8260-8 [18922897.001]
  • (PMID = 19880689.001).
  • [ISSN] 1942-5546
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunologic Factors
  • [Number-of-references] 263
  • [Other-IDs] NLM/ PMC2770910
  •  go-up   go-down


23. Beck IM, Vanden Berghe W, Vermeulen L, Yamamoto KR, Haegeman G, De Bosscher K: Crosstalk in inflammation: the interplay of glucocorticoid receptor-based mechanisms and kinases and phosphatases. Endocr Rev; 2009 Dec;30(7):830-82
MedlinePlus Health Information. consumer health - Steroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These steroidal ligands and derivatives thereof are the first line of treatment in a vast array of inflammatory diseases.
  • Moreover, kinase inhibitors have become increasingly important as antiinflammatory tools, not only for research but also for therapeutic purposes.
  • In light of these developments, we aim to illuminate the integrated interplay between GR signaling and its correlating kinases and phosphatases in the context of the clinically important combat of inflammation, giving attention to implications on GC-mediated side effects and therapy resistance.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1991 Feb 15;266(5):3107-12 [1993683.001]
  • [Cites] J Biol Chem. 1991 Apr 25;266(12):7549-55 [2019585.001]
  • [Cites] Mol Cell Biol. 1991 Jun;11(6):3379-83 [2038339.001]
  • [Cites] Nature. 1991 Aug 8;352(6335):497-505 [1865905.001]
  • [Cites] Cytokine. 1990 Nov;2(6):402-6 [2129506.001]
  • [Cites] Cell. 1991 Nov 29;67(5):977-86 [1683601.001]
  • [Cites] Blood. 1992 Jan 1;79(1):45-51 [1370208.001]
  • [Cites] Mol Endocrinol. 1991 Sep;5(9):1215-28 [1663212.001]
  • [Cites] Trends Biochem Sci. 1991 Nov;16(11):423-6 [1776172.001]
  • [Cites] Mol Endocrinol. 1992 Jan;6(1):26-34 [1310797.001]
  • [Cites] Genes Dev. 1992 Sep;6(9):1810-9 [1516835.001]
  • [Cites] Mol Endocrinol. 1992 Sep;6(9):1451-7 [1435789.001]
  • [Cites] Br J Cancer. 1993 Jan;67(1):99-101 [8427785.001]
  • [Cites] Cell. 1993 Mar 12;72(5):729-39 [8453667.001]
  • [Cites] Immunology. 1993 May;79(1):24-31 [8389730.001]
  • [Cites] FASEB J. 1993 Oct;7(13):1283-92 [8405814.001]
  • [Cites] J Mol Biol. 1994 Jun 24;239(5):664-88 [8014988.001]
  • [Cites] EMBO J. 1994 Sep 1;13(17):4087-95 [8076604.001]
  • [Cites] Mol Cell Biochem. 1994 Mar 30;132(2):163-71 [7969099.001]
  • [Cites] Genes Dev. 1994 Dec 1;8(23):2842-56 [7995522.001]
  • [Cites] Cell. 1995 Jan 27;80(2):331-40 [7834753.001]
  • [Cites] EMBO J. 1995 Feb 1;14(3):452-60 [7859735.001]
  • [Cites] J Steroid Biochem Mol Biol. 1995 Feb;52(2):135-40 [7873448.001]
  • [Cites] Science. 1995 Mar 10;267(5203):1485-8 [7878466.001]
  • [Cites] J Immunol. 1995 Apr 1;154(7):3500-5 [7897230.001]
  • [Cites] Carcinogenesis. 1995 Mar;16(3):443-50 [7697796.001]
  • [Cites] Cell. 1997 May 2;89(3):413-24 [9150141.001]
  • [Cites] J Cell Biol. 1997 May 5;137(3):523-38 [9151662.001]
  • [Cites] Mol Cell Biol. 1997 Jun;17(6):3181-93 [9154817.001]
  • [Cites] J Biol Chem. 1997 Jun 13;272(24):15366-72 [9182566.001]
  • [Cites] J Biol Chem. 1997 Jun 27;272(26):16224-30 [9195923.001]
  • [Cites] Mol Cell Biol. 1997 Jul;17(7):3947-54 [9199329.001]
  • [Cites] J Cell Biol. 1997 Jun 30;137(7):1627-38 [9199176.001]
  • [Cites] Mol Endocrinol. 1997 Aug;11(9):1245-55 [9259316.001]
  • [Cites] J Biol Chem. 1997 Aug 22;272(34):21467-72 [9261164.001]
  • [Cites] Mol Cell Biol. 2003 Nov;23(21):7780-93 [14560022.001]
  • [Cites] Mol Cell Biol. 1997 Nov;17(11):6274-82 [9343388.001]
  • [Cites] Mol Cell Endocrinol. 2009 Jan 27;298(1-2):66-75 [19007849.001]
  • [Cites] Mol Endocrinol. 2009 Jan;23(1):86-99 [18945810.001]
  • [Cites] Nat Rev Cancer. 2008 Sep;8(9):683-93 [19143053.001]
  • [Cites] Genes Dev. 2008 Dec 15;22(24):3375-82 [19141469.001]
  • [Cites] Genes Dev. 2008 Dec 15;22(24):3391-6 [19141471.001]
  • [Cites] Am J Respir Cell Mol Biol. 2009 Feb;40(2):223-30 [18776133.001]
  • [Cites] Blood. 2009 Jan 15;113(3):575-84 [18840710.001]
  • [Cites] Immunol Rev. 2008 Dec;226:10-8 [19161412.001]
  • [Cites] J Clin Apher. 2003;18(3):141-52 [14569608.001]
  • [Cites] EMBO J. 2003 Nov 17;22(22):6035-44 [14609950.001]
  • [Cites] FEBS Lett. 2003 Nov 20;554(3):489-93 [14623117.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):13845-50 [14617768.001]
  • [Cites] Mol Endocrinol. 2003 Dec;17(12):2583-92 [12933902.001]
  • [Cites] Nat Rev Cancer. 2003 Nov;3(11):859-68 [14668816.001]
  • [Cites] J Biol Chem. 2003 Dec 19;278(51):50897-901 [14534302.001]
  • [Cites] Mol Cell. 2003 Dec;12(6):1413-26 [14690596.001]
  • [Cites] Mol Endocrinol. 2004 Jan;18(1):53-62 [14551261.001]
  • [Cites] Mol Psychiatry. 2004 Jan;9(1):65-75 [14699442.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):233-8 [14679297.001]
  • [Cites] Science. 2004 Jun 25;304(5679):1963-7 [15218148.001]
  • [Cites] Mol Endocrinol. 2004 Jul;18(7):1697-707 [15184525.001]
  • [Cites] J Exp Med. 2004 Jul 5;200(1):107-13 [15226358.001]
  • [Cites] J Mol Med (Berl). 2004 Jul;82(7):434-48 [15175863.001]
  • [Cites] Essays Biochem. 2004;40:41-58 [15242338.001]
  • [Cites] J Biol Chem. 2004 Jul 16;279(29):30099-105 [15140882.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1024:86-101 [15265775.001]
  • [Cites] Clin Sci (Lond). 2004 Aug;107(2):111-23 [15113280.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2004 Aug;287(2):E275-81 [15039148.001]
  • [Cites] Mol Cell Biol. 2004 Sep;24(17):7806-19 [15314185.001]
  • [Cites] Cell. 2004 Aug 20;118(4):453-64 [15315758.001]
  • [Cites] J Biol Chem. 2004 Sep 10;279(37):38134-42 [15234985.001]
  • [Cites] Genes Dev. 2004 Sep 15;18(18):2195-224 [15371334.001]
  • [Cites] Bioorg Med Chem Lett. 2004 Oct 18;14(20):5199-203 [15380227.001]
  • [Cites] Curr Pharm Des. 2004;10(23):2807-16 [15379669.001]
  • [Cites] J Biol Chem. 2004 Oct 15;279(42):43708-15 [15292225.001]
  • [Cites] Genes Dev. 2004 Oct 15;18(20):2518-28 [15489293.001]
  • [Cites] Science. 2004 Oct 22;306(5696):704-8 [15499023.001]
  • [Cites] Cell. 1975 Nov;6(3):299-305 [212202.001]
  • [Cites] Nature. 1985 Dec 19-1986 Jan 1;318(6047):635-41 [2867473.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Aug;83(16):5899-903 [3016728.001]
  • [Cites] EMBO J. 1987 Nov;6(11):3333-40 [3123217.001]
  • [Cites] Cell. 1988 Dec 2;55(5):899-906 [3191531.001]
  • [Cites] Cancer Res. 1989 Apr 15;49(8 Suppl):2295s-2302s [2702670.001]
  • [Cites] J Biol Chem. 1989 Aug 25;264(24):14396-402 [2668288.001]
  • [Cites] Genes Dev. 1989 Oct;3(10):1590-601 [2515114.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):3919-24 [10760263.001]
  • [Cites] J Biol Chem. 2000 Apr 28;275(17):12470-4 [10777532.001]
  • [Cites] J Biol Chem. 2000 May 12;275(19):14608-14 [10799547.001]
  • [Cites] J Allergy Clin Immunol. 2000 May;105(5):943-50 [10808175.001]
  • [Cites] J Steroid Biochem Mol Biol. 2000 Apr;72(5):209-21 [10822010.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2000 Jul;279(1):E74-82 [10893325.001]
  • [Cites] Mol Cell Biol. 2000 Aug;20(16):6040-50 [10913186.001]
  • [Cites] J Biol Chem. 2000 Aug 4;275(31):23549-58 [10806207.001]
  • [Cites] J Biol Chem. 2000 Aug 11;275(32):24392-9 [10825175.001]
  • [Cites] Mol Endocrinol. 2000 Aug;14(8):1222-34 [10935546.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9573-8 [10920190.001]
  • [Cites] Mol Cell Biol. 2000 Sep;20(18):6891-903 [10958685.001]
  • [Cites] J Mol Biol. 2000 Aug 25;301(4):947-58 [10966797.001]
  • [Cites] J Cell Biol. 2000 Sep 4;150(5):1199-208 [10974006.001]
  • [Cites] Genes Dev. 2000 Sep 15;14(18):2314-29 [10995388.001]
  • [Cites] Mol Cell Endocrinol. 2000 Aug 30;166(2):129-36 [10996431.001]
  • [Cites] J Biol Chem. 2000 Oct 20;275(42):32592-7 [10938077.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):11893-8 [11027313.001]
  • [Cites] J Biol Chem. 2000 Dec 15;275(50):39296-301 [11005817.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):227-32 [14694204.001]
  • [Cites] Transplantation. 2004 Jan 27;77(2):259-67 [14742991.001]
  • [Cites] J Clin Invest. 2004 Feb;113(4):619-27 [14966571.001]
  • [Cites] J Biol Chem. 2004 Feb 27;279(9):7685-91 [14670976.001]
  • [Cites] J Biol Chem. 2004 Mar 12;279(11):10176-84 [14688255.001]
  • [Cites] Mol Cell Biol. 2004 Apr;24(7):2682-97 [15024059.001]
  • [Cites] EMBO J. 2004 Mar 24;23(6):1313-24 [15014438.001]
  • [Cites] Mol Endocrinol. 2004 Apr;18(4):820-33 [14739255.001]
  • [Cites] Diabetes. 2004 Apr;53(4):899-910 [15047604.001]
  • [Cites] Oncogene. 2004 Apr 1;23(14):2540-7 [14676825.001]
  • [Cites] Mol Biol Cell. 2004 May;15(5):2276-86 [15004228.001]
  • [Cites] J Biol Chem. 2004 Apr 30;279(18):18457-66 [14976190.001]
  • [Cites] Biochim Biophys Acta. 2004 May 3;1691(2-3):73-7 [15110988.001]
  • [Cites] J Med Chem. 2004 May 6;47(10):2441-52 [15115388.001]
  • [Cites] J Immunol. 2004 May 15;172(10):6336-44 [15128824.001]
  • [Cites] Science. 1990 Jul 13;249(4965):157-60 [2115209.001]
  • [Cites] Science. 1990 Sep 14;249(4974):1266-72 [2119054.001]
  • [Cites] Cell. 1990 Sep 21;62(6):1217-26 [2169353.001]
  • [Cites] J Clin Invest. 1990 Dec;86(6):1945-53 [2254454.001]
  • [Cites] Endocrinology. 1995 Dec;136(12):5476-84 [7588298.001]
  • [Cites] J Exp Med. 1995 Dec 1;182(6):1951-8 [7500041.001]
  • [Cites] Endocr J. 1995 Oct;42(5):629-36 [8574285.001]
  • [Cites] Cell. 1995 Dec 29;83(7):1091-100 [8548797.001]
  • [Cites] J Immunol. 1996 Feb 1;156(3):1166-73 [8557994.001]
  • [Cites] Cell. 1996 Jan 26;84(2):299-308 [8565075.001]
  • [Cites] Immunity. 1996 Apr;4(4):387-96 [8612133.001]
  • [Cites] Immunity. 1996 May;4(5):445-54 [8630730.001]
  • [Cites] J Biol Chem. 1996 Jul 12;271(28):16591-6 [8663179.001]
  • [Cites] Science. 1996 Aug 9;273(5276):792-4 [8670418.001]
  • [Cites] Funct Neurol. 1995 Jul-Oct;10(4-5):183-94 [8749045.001]
  • [Cites] J Immunol. 1996 Sep 15;157(6):2374-80 [8805635.001]
  • [Cites] Curr Biol. 1996 Jan 1;6(1):16-9 [8805215.001]
  • [Cites] Mol Cell Endocrinol. 1996 Jul 1;120(2):139-46 [8832573.001]
  • [Cites] Nature. 1996 Oct 24;383(6602):726-8 [8878484.001]
  • [Cites] Mol Endocrinol. 1996 Oct;10(10):1191-205 [9121487.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Nov 21;228(3):831-7 [8941362.001]
  • [Cites] Cell. 1996 Nov 29;87(5):929-39 [8945519.001]
  • [Cites] EMBO J. 1996 Nov 15;15(22):6189-96 [8947041.001]
  • [Cites] J Biol Chem. 1996 Dec 13;271(50):32315-20 [8943293.001]
  • [Cites] Trends Biochem Sci. 1996 Nov;21(11):407-12 [8987393.001]
  • [Cites] Science. 1997 Jan 24;275(5299):523-7 [8999795.001]
  • [Cites] Nature. 1997 Feb 6;385(6616):540-4 [9020361.001]
  • [Cites] J Exp Med. 1996 Sep 1;184(3):839-52 [9064344.001]
  • [Cites] J Biol Chem. 1997 Apr 4;272(14):9287-93 [9083064.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):2927-32 [9096323.001]
  • [Cites] Nat Immunol. 2002 Jan;3(1):20-6 [11753406.001]
  • [Cites] FASEB J. 2002 Jan;16(1):61-71 [11772937.001]
  • [Cites] J Biol Chem. 2002 Jan 4;277(1):5-8 [11696533.001]
  • [Cites] J Biol Chem. 2002 Jan 11;277(2):1405-18 [11687592.001]
  • [Cites] J Biol Chem. 2002 Jan 25;277(4):2525-33 [11705993.001]
  • [Cites] J Biol Chem. 2002 Feb 1;277(5):3065-8 [11741878.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Jan;3(1):30-40 [11823796.001]
  • [Cites] J Biol Chem. 2002 Feb 8;277(6):3863-9 [11733537.001]
  • [Cites] J Biol Chem. 2002 Feb 22;277(8):6391-8 [11698396.001]
  • [Cites] Annu Rev Immunol. 2002;20:55-72 [11861597.001]
  • [Cites] Mol Cell. 2002 Feb;9(2):401-10 [11864612.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2002 Apr;282(4):L631-41 [11880287.001]
  • [Cites] J Biol Chem. 2002 Mar 15;277(11):8810-6 [11777913.001]
  • [Cites] Int Rev Cytol. 2002;214:225-72 [11893167.001]
  • [Cites] Curr Opin Genet Dev. 2002 Apr;12(2):198-209 [11893494.001]
  • [Cites] Mol Cell Biol. 2002 Apr;22(8):2871-81 [11909979.001]
  • [Cites] J Biol Chem. 2002 Mar 29;277(13):10876-82 [11751935.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4221-6 [11904383.001]
  • [Cites] Mol Cell. 2002 Mar;9(3):625-36 [11931769.001]
  • [Cites] PLoS One. 2009;4(2):e4393 [19197368.001]
  • [Cites] Biochem Pharmacol. 2009 Feb 15;77(4):734-45 [18955032.001]
  • [Cites] Biochem Pharmacol. 2009 Feb 15;77(4):670-80 [19014911.001]
  • [Cites] J Biol Chem. 2009 Feb 13;284(7):4073-89 [19088076.001]
  • [Cites] J Immunol. 2009 Feb 15;182(4):2385-94 [19201893.001]
  • [Cites] Biol Cell. 2009 Apr;101(4):193-205 [19207105.001]
  • [Cites] Mol Cell Endocrinol. 2009 Mar 5;300(1-2):7-16 [19000736.001]
  • [Cites] J Bone Miner Metab. 2009;27(2):140-8 [19066717.001]
  • [Cites] Mol Endocrinol. 2009 Mar;23(3):281-91 [19095768.001]
  • [Cites] Biochem Pharmacol. 2009 Apr 1;77(7):1194-205 [19150610.001]
  • [Cites] Mol Cell. 2009 Mar 13;33(5):537-45 [19285938.001]
  • [Cites] Trends Immunol. 2004 Jun;25(6):280-8 [15145317.001]
  • [Cites] Obes Res. 2004 May;12(5):862-70 [15166308.001]
  • [Cites] Microbiol Mol Biol Rev. 2004 Jun;68(2):320-44 [15187187.001]
  • [Cites] J Biol Chem. 2004 Jun 18;279(25):26143-8 [15073167.001]
  • [Cites] J Biol Chem. 2004 Jun 18;279(25):26115-25 [15073170.001]
  • [Cites] Vitam Horm. 2004;68:49-91 [15193451.001]
  • [Cites] J Allergy Clin Immunol. 2004 Jun;113(6):1100-8 [15208591.001]
  • [Cites] J Exp Med. 2004 Jun 21;199(12):1641-50 [15210742.001]
  • [Cites] Semin Fetal Neonatal Med. 2009 Jun;14(3):127-9 [19246269.001]
  • [Cites] Science. 2009 Apr 3;324(5923):95-8 [19342589.001]
  • [Cites] Bioessays. 2009 May;31(5):561-9 [19319913.001]
  • [Cites] Leukemia. 2009 Apr;23(4):746-52 [19148136.001]
  • [Cites] Leukemia. 2009 Apr;23(4):820-3 [19151768.001]
  • [Cites] Science. 2009 Apr 17;324(5925):407-10 [19372434.001]
  • [Cites] Endocrinology. 2009 May;150(5):2220-8 [19131573.001]
  • [Cites] FASEB J. 2009 May;23(5):1558-71 [19124555.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 May 5;106(18):7397-402 [19376972.001]
  • [Cites] EMBO J. 2009 May 20;28(10):1392-406 [19369945.001]
  • [Cites] Endocrinology. 2009 Jun;150(6):2700-8 [19179438.001]
  • [Cites] Trends Biochem Sci. 2009 Jun;34(6):311-8 [19464896.001]
  • [Cites] J Endocrinol. 2009 Jul;202(1):87-97 [19406955.001]
  • [Cites] Clin Sci (Lond). 2009 Oct;117(8):305-12 [19267693.001]
  • [Cites] J Biol Chem. 2009 Sep 4;284(36):24542-52 [19586900.001]
  • [Cites] Ann Rheum Dis. 2010 Jan;69(1):291-6 [19204014.001]
  • [Cites] Oncogene. 1999 Nov 18;18(48):6733-40 [10597281.001]
  • [Cites] Science. 1999 Dec 24;286(5449):2514-7 [10617468.001]
  • [Cites] Mol Endocrinol. 2000 Jan;14(1):40-51 [10628746.001]
  • [Cites] APMIS. 1999 Dec;107(12):1124-30 [10660143.001]
  • [Cites] FASEB J. 2000 Jan;14(1):6-16 [10627275.001]
  • [Cites] J Immunol. 2000 Feb 15;164(4):1768-74 [10657623.001]
  • [Cites] Science. 2000 Feb 18;287(5456):1262-5 [10678832.001]
  • [Cites] J Biol Chem. 2000 Feb 25;275(8):5804-9 [10681569.001]
  • [Cites] J Biol Chem. 2000 Mar 10;275(10):7066-70 [10702272.001]
  • [Cites] Mol Cell Biol. 2000 Apr;20(8):2629-34 [10733565.001]
  • [Cites] Cell Signal. 2003 Apr;15(4):355-66 [12618210.001]
  • [Cites] J Biol Chem. 2003 Mar 14;278(11):9441-7 [12524442.001]
  • [Cites] EMBO J. 2003 Mar 17;22(6):1313-24 [12628924.001]
  • [Cites] J Mol Med (Berl). 2003 Mar;81(3):168-74 [12682725.001]
  • [Cites] Mol Endocrinol. 2003 May;17(5):860-9 [12586843.001]
  • [Cites] J Steroid Biochem Mol Biol. 2003 Mar;84(4):441-52 [12732289.001]
  • [Cites] Mol Cell Biol. 2003 Jun;23(11):3763-73 [12748280.001]
  • [Cites] J Immunol. 2003 Jun 1;170(11):5681-9 [12759450.001]
  • [Cites] EMBO J. 2003 Jun 2;22(11):2788-97 [12773393.001]
  • [Cites] Nature. 2003 Jun 5;423(6940):655-9 [12789342.001]
  • [Cites] Nature. 2003 Jun 5;423(6940):659-63 [12789343.001]
  • [Cites] J Biol Chem. 2003 Jun 13;278(24):21534-41 [12676937.001]
  • [Cites] J Biol Chem. 2003 Jun 27;278(26):23278-84 [12709443.001]
  • [Cites] EMBO J. 2003 Aug 1;22(15):3910-8 [12881425.001]
  • [Cites] Sci STKE. 2003 Aug 12;2003(195):PE33 [12915720.001]
  • [Cites] Mol Cell Biol. 2003 Sep;23(17):6129-38 [12917335.001]
  • [Cites] Nature. 2003 Aug 14;424(6950):801-5 [12917691.001]
  • [Cites] Endocr Rev. 2003 Aug;24(4):488-522 [12920152.001]
  • [Cites] Am J Pathol. 2003 Sep;163(3):833-43 [12937125.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2001 Jan;280(1):L107-15 [11133500.001]
  • [Cites] J Immunol. 2001 Jan 15;166(2):966-72 [11145674.001]
  • [Cites] Mol Cell Biol. 2001 Feb;21(3):771-80 [11154265.001]
  • [Cites] Arthritis Res. 2000;2(5):356-60 [11094448.001]
  • [Cites] Cell. 2000 Dec 22;103(7):1071-83 [11163183.001]
  • [Cites] J Biol Chem. 2001 Feb 23;276(8):5892-9 [11035004.001]
  • [Cites] J Immunol. 2001 Feb 1;166(3):1975-82 [11160246.001]
  • [Cites] Mol Endocrinol. 2001 Feb;15(2):219-27 [11158329.001]
  • [Cites] J Endocrinol. 2001 Apr;169(1):11-22 [11250642.001]
  • [Cites] FASEB J. 2001 Mar;15(3):693-9 [11259387.001]
  • [Cites] Eur J Clin Invest. 2000 Dec;30 Suppl 3:51-4 [11281368.001]
  • [Cites] J Rheumatol. 1995 Jan;22(1):124-32 [7535358.001]
  • [Cites] Mol Endocrinol. 1994 Dec;8(12):1764-73 [7708063.001]
  • [Cites] J Mol Biol. 1995 Apr 7;247(4):689-700 [7723024.001]
  • [Cites] Cell. 1995 May 19;81(4):495-504 [7758105.001]
  • [Cites] Mol Endocrinol. 1995 Apr;9(4):401-12 [7659084.001]
  • [Cites] Mol Cell Biol. 1995 Oct;15(10):5346-54 [7565684.001]
  • [Cites] EMBO J. 1995 Oct 2;14(19):4758-62 [7588605.001]
  • [Cites] Int Immunol. 1995 Apr;7(4):517-23 [7547677.001]
  • [Cites] J Exp Med. 2001 Jun 18;193(12):1351-9 [11413190.001]
  • [Cites] Mol Cell Biol. 2001 Jul;21(14):4837-46 [11416157.001]
  • [Cites] Nat Immunol. 2001 Jul;2(7):620-4 [11429546.001]
  • [Cites] Mol Cell Biol. 2001 Aug;21(16):5417-25 [11463824.001]
  • [Cites] Blood. 2001 Aug 1;98(3):743-53 [11468175.001]
  • [Cites] J Biol Chem. 2001 Aug 3;276(31):29603-10 [11397794.001]
  • [Cites] Gene. 2001 Jul 25;273(1):1-11 [11483355.001]
  • [Cites] Trends Cell Biol. 2001 Sep;11(9):372-7 [11514191.001]
  • [Cites] Science. 2001 Aug 24;293(5534):1495-9 [11520989.001]
  • [Cites] Science. 2001 Aug 31;293(5535):1653-7 [11533489.001]
  • [Cites] Mol Cell. 2001 Aug;8(2):327-37 [11545735.001]
  • [Cites] Eur J Neurosci. 2001 Aug;14(4):675-89 [11556892.001]
  • [Cites] Mol Cell Biol. 2001 Oct;21(20):7065-77 [11564889.001]
  • [Cites] Mol Cell Biol. 2001 Oct;21(20):7089-96 [11564891.001]
  • [Cites] J Biol Chem. 2001 Sep 28;276(39):36467-73 [11479299.001]
  • [Cites] Mol Cell. 2001 Oct;8(4):771-80 [11684013.001]
  • [Cites] EMBO J. 2001 Nov 1;20(21):6071-83 [11689447.001]
  • [Cites] J Biol Chem. 2001 Nov 9;276(45):42580-7 [11546803.001]
  • [Cites] Mol Biol Cell. 2001 Nov;12(11):3365-74 [11694573.001]
  • [Cites] J Clin Invest. 2001 Nov;108(9):1359-67 [11696581.001]
  • [Cites] Eur J Pharmacol. 2001 Oct 19;429(1-3):327-34 [11698053.001]
  • [Cites] J Biol Chem. 2001 Nov 16;276(46):42714-21 [11555652.001]
  • [Cites] EMBO J. 2001 Dec 17;20(24):7052-9 [11742982.001]
  • [Cites] EMBO J. 2001 Dec 17;20(24):7108-16 [11742987.001]
  • [Cites] EMBO J. 2001 Dec 17;20(24):7168-73 [11742993.001]
  • [Cites] J Biol Chem. 2001 Dec 21;276(51):47828-33 [11591705.001]
  • [Cites] J Biol Chem. 1999 Feb 5;274(6):3496-502 [9920895.001]
  • [Cites] J Biol Chem. 1999 Feb 26;274(9):5880-7 [10026211.001]
  • [Cites] Hepatology. 1999 Mar;29(3):849-57 [10051489.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2514-9 [10051674.001]
  • [Cites] Science. 1999 Apr 9;284(5412):316-20 [10195896.001]
  • [Cites] J Biol Chem. 1999 Apr 9;274(15):10641-8 [10187861.001]
  • [Cites] J Biol Chem. 1999 Apr 30;274(18):12431-7 [10212217.001]
  • [Cites] J Biol Chem. 1999 May 7;274(19):13033-40 [10224054.001]
  • [Cites] Steroids. 1999 Jan-Feb;64(1-2):107-19 [10323679.001]
  • [Cites] Trends Biochem Sci. 1999 May;24(5):186-91 [10322434.001]
  • [Cites] Genes Dev. 1999 May 15;13(10):1322-8 [10346820.001]
  • [Cites] J Biol Chem. 1999 Jun 4;274(23):16222-7 [10347177.001]
  • [Cites] Steroids. 1999 May;64(5):310-9 [10406480.001]
  • [Cites] Biochemistry. 1999 Jul 13;38(28):8849-57 [10413457.001]
  • [Cites] Mol Cell Biol. 1999 Sep;19(9):6367-78 [10454583.001]
  • [Cites] J Allergy Clin Immunol. 1999 Sep;104(3 Pt 1):565-74 [10482829.001]
  • [Cites] Mol Pharmacol. 1999 Oct;56(4):797-806 [10496964.001]
  • [Cites] EMBO J. 1999 Oct 1;18(19):5380-8 [10508170.001]
  • [Cites] Mol Endocrinol. 1999 Oct;13(10):1629-44 [10517666.001]
  • [Cites] J Allergy Clin Immunol. 2002 Apr;109(4):649-57 [11941315.001]
  • [Cites] Cell. 2002 Apr;109 Suppl:S81-96 [11983155.001]
  • [Cites] Nat Med. 2002 May;8(5):473-9 [11984591.001]
  • [Cites] Mol Cell Biol. 2002 Jun;22(12):4113-23 [12024025.001]
  • [Cites] Science. 2002 May 31;296(5573):1634-5 [12040173.001]
  • [Cites] Biochem Biophys Res Commun. 2002 May 17;293(4):1254-61 [12054511.001]
  • [Cites] Endocrinology. 2002 Jul;143(7):2461-5 [12072374.001]
  • [Cites] Science. 2002 Jun 21;296(5576):2232-5 [12077419.001]
  • [Cites] J Biol Chem. 2002 Jul 5;277(27):24701-8 [11970949.001]
  • [Cites] Bone. 2002 Jul;31(1):220-9 [12110438.001]
  • [Cites] J Biol Chem. 2002 Jul 19;277(29):26573-80 [12000743.001]
  • [Cites] J Med Chem. 2009 Mar 26;52(6):1731-43 [19239259.001]
  • [Cites] Am J Respir Crit Care Med. 2009 Apr 1;179(7):572-8 [19136372.001]
  • [Cites] Am J Respir Crit Care Med. 2009 Apr 1;179(7):542-8 [19164702.001]
  • [Cites] Am J Respir Crit Care Med. 2009 Apr 1;179(7):523-4 [19318540.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4882-7 [19225110.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4577-8 [19293386.001]
  • [Cites] Semin Fetal Neonatal Med. 2009 Jun;14(3):136-42 [19073374.001]
  • [Cites] Semin Fetal Neonatal Med. 2009 Jun;14(3):143-50 [19217839.001]
  • [Cites] Ernst Schering Res Found Workshop. 2002;(40):357-71 [12355726.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2002 Nov;283(5):E971-9 [12376324.001]
  • [Cites] Mol Cell Biol. 2002 Nov;22(22):7802-11 [12391149.001]
  • [Cites] Mol Cell Biol. 2002 Nov;22(22):7929-41 [12391160.001]
  • [Cites] Biochem J. 2002 Nov 1;367(Pt 3):907-11 [12144530.001]
  • [Cites] J Biol Chem. 2002 Oct 25;277(43):40697-702 [12185077.001]
  • [Cites] Int Immunopharmacol. 2002 Sep;2(10):1419-27 [12400872.001]
  • [Cites] FASEB J. 2002 Nov;16(13):1832-4 [12223450.001]
  • [Cites] Pharmacol Ther. 2002 Oct;96(1):23-43 [12441176.001]
  • [Cites] J Immunol. 2002 Dec 1;169(11):6408-16 [12444149.001]
  • [Cites] EMBO J. 2002 Dec 2;21(23):6539-48 [12456660.001]
  • [Cites] J Allergy Clin Immunol. 2002 Dec;110(6 Suppl):S261-8 [12464934.001]
  • [Cites] J Clin Invest. 2002 Dec;110(11):1729-38 [12464678.001]
  • [Cites] J Biochem Mol Biol. 2002 Nov 30;35(6):537-46 [12470586.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16701-6 [12481024.001]
  • [Cites] Blood. 2003 Jan 15;101(2):729-38 [12393603.001]
  • [Cites] J Biol Chem. 2003 Jan 10;278(2):919-26 [12419817.001]
  • [Cites] J Allergy Clin Immunol. 2003 Jan;111(1):3-22; quiz 23 [12532089.001]
  • [Cites] J Biol Chem. 2003 Jan 24;278(4):2758-66 [12419806.001]
  • [Cites] Endocrinology. 2003 Feb;144(2):412-22 [12538600.001]
  • [Cites] J Cell Sci. 2003 Feb 15;116(Pt 4):585-6 [12538758.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jan 24;300(4):807-12 [12559944.001]
  • [Cites] FEBS Lett. 2003 Feb 11;536(1-3):135-40 [12586352.001]
  • [Cites] J Biol Chem. 2003 Feb 21;278(8):5622-9 [12441346.001]
  • [Cites] Mol Biol Cell. 2003 Feb;14(2):491-502 [12589049.001]
  • [Cites] Mol Cell Biol. 2003 Mar;23(6):1922-34 [12612067.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Jul;6(7):542-54 [15957004.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1703-10 [15899916.001]
  • [Cites] Proc Am Thorac Soc. 2004;1(3):255-63 [16113443.001]
  • [Cites] Biochem J. 2005 Sep 15;390(Pt 3):749-59 [15910281.001]
  • [Cites] Mol Cell Biol. 2005 Sep;25(18):7966-75 [16135789.001]
  • [Cites] Cell. 2005 Sep 9;122(5):707-21 [16143103.001]
  • [Cites] Am J Respir Crit Care Med. 2005 Sep 15;172(6):704-12 [15860753.001]
  • [Cites] Am J Physiol Cell Physiol. 2005 Oct;289(4):C802-10 [15888551.001]
  • [Cites] Immunity. 2005 Sep;23(3):319-29 [16169504.001]
  • [Cites] FASEB J. 2005 Oct;19(12):1758-60 [16046471.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Nov 4;336(4):1049-55 [16165091.001]
  • [Cites] J Biol Chem. 2005 Oct 14;280(41):34538-47 [16105840.001]
  • [Cites] BMC Genomics. 2005;6:137 [16191192.001]
  • [Cites] Eur J Immunol. 2005 Oct;35(10):2991-3001 [16184516.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1711-23 [16236742.001]
  • [Cites] Mol Cell. 2005 Oct 28;20(2):199-211 [16246723.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):15827-32 [16243974.001]
  • [Cites] Mol Cell Biol. 2005 Dec;25(23):10454-64 [16287858.001]
  • [Cites] J Biol Chem. 2005 Dec 2;280(48):39970-81 [16216878.001]
  • [Cites] FEBS Lett. 2003 Sep 11;551(1-3):8-12 [12965196.001]
  • [Cites] J Endocrinol. 2003 Sep;178(3):347-55 [12967328.001]
  • [Cites] J Biol Chem. 2003 Sep 26;278(39):37858-64 [12869547.001]
  • [Cites] J Biol Chem. 2003 Oct 10;278(41):39470-6 [12882963.001]
  • [Cites] EMBO J. 2003 Oct 15;22(20):5530-9 [14532125.001]
  • [Cites] Biochem Pharmacol. 2003 Oct 15;66(8):1403-8 [14555214.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13504-9 [9391055.001]
  • [Cites] Genes Dev. 1997 Dec 15;11(24):3351-64 [9407028.001]
  • [Cites] J Biol Chem. 1997 Dec 19;272(51):32606-12 [9405476.001]
  • [Cites] Immunity. 1997 Dec;7(6):803-12 [9430225.001]
  • [Cites] Mol Endocrinol. 1998 Jan;12(1):45-56 [9440809.001]
  • [Cites] Mol Cell Biol. 2001 May;21(9):3266-79 [11287629.001]
  • [Cites] Trends Endocrinol Metab. 2001 Apr;12(3):122-6 [11306337.001]
  • [Cites] J Biol Chem. 2001 May 4;276(18):14884-9 [11278753.001]
  • [Cites] J Clin Endocrinol Metab. 2001 May;86(5):2136-43 [11344218.001]
  • [Cites] Mol Cell Biol. 2001 Jun;21(12):3986-94 [11359906.001]
  • [Cites] J Biol Chem. 2001 May 18;276(20):16649-54 [11278764.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6865-70 [11381138.001]
  • [Cites] Oncogene. 2001 Apr 30;20(19):2453-64 [11402340.001]
  • [Cites] J Biol Chem. 1998 May 1;273(18):10831-4 [9556555.001]
  • [Cites] Nature. 1998 Apr 30;392(6679):885-8 [9582068.001]
  • [Cites] Nature. 1998 May 7;393(6680):88-91 [9590696.001]
  • [Cites] Annu Rev Immunol. 1998;16:225-60 [9597130.001]
  • [Cites] Cell. 1998 May 15;93(4):531-41 [9604929.001]
  • [Cites] J Biol Chem. 1998 Jun 5;273(23):14315-21 [9603939.001]
  • [Cites] Science. 1998 Jun 19;280(5371):1945-9 [9632395.001]
  • [Cites] Mol Cell. 1998 Apr;1(5):661-71 [9660950.001]
  • [Cites] EMBO J. 1998 Aug 3;17(15):4426-41 [9687510.001]
  • [Cites] Science. 1998 Aug 14;281(5379):1001-5 [9703499.001]
  • [Cites] J Biol Chem. 1998 Sep 4;273(36):23567-74 [9722596.001]
  • [Cites] EMBO J. 1998 Oct 15;17(20):6039-48 [9774347.001]
  • [Cites] J Biol Chem. 1998 Nov 6;273(45):29291-4 [9792627.001]
  • [Cites] J Biol Chem. 1998 Nov 6;273(45):29411-6 [9792644.001]
  • [Cites] J Biol Chem. 1998 Nov 6;273(45):29417-23 [9792645.001]
  • [Cites] J Biol Chem. 1998 Nov 13;273(46):30081-5 [9804760.001]
  • [Cites] Genes Dev. 1998 Nov 1;12(21):3343-56 [9808622.001]
  • [Cites] J Biol Chem. 1998 Nov 27;273(48):32312-21 [9822711.001]
  • [Cites] J Biol Chem. 1998 Dec 11;273(50):33561-5 [9837938.001]
  • [Cites] J Allergy Clin Immunol. 1998 Nov;102(5):714-8 [9867498.001]
  • [Cites] J Clin Invest. 1998 Dec 15;102(12):2156-64 [9854051.001]
  • [Cites] Pharmacol Rev. 1998 Dec;50(4):515-96 [9860804.001]
  • [Cites] J Biol Chem. 1999 Jan 8;274(2):1005-10 [9873044.001]
  • [Cites] FEBS Lett. 1998 Dec 18;441(2):275-80 [9883899.001]
  • [Cites] J Biol Chem. 1999 Jan 15;274(3):1432-9 [9880517.001]
  • [Cites] Mol Cell Biol. 1999 Feb;19(2):1025-37 [9891038.001]
  • [Cites] J Exp Med. 2006 Aug 7;203(8):1883-9 [16880258.001]
  • [Cites] In Vivo. 2006 Jul-Aug;20(4):467-72 [16900776.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12481-6 [16885212.001]
  • [Cites] Lab Invest. 2006 Sep;86(9):867-72 [16865089.001]
  • [Cites] Nat Rev Immunol. 2006 Sep;6(9):644-58 [16932750.001]
  • [Cites] Mol Endocrinol. 2006 Sep;20(9):1972-81 [16423879.001]
  • [Cites] Am J Physiol Renal Physiol. 2006 Oct;291(4):F714-21 [16720863.001]
  • [Cites] J Biol Chem. 2006 Sep 15;281(37):26976-84 [16840782.001]
  • [Cites] Pharmacol Rev. 2006 Sep;58(3):621-81 [16968952.001]
  • [Cites] Trends Endocrinol Metab. 2006 Oct;17(8):321-7 [16942889.001]
  • [Cites] Mol Endocrinol. 2006 Oct;20(10):2304-14 [16690749.001]
  • [Cites] Biochem Pharmacol. 2006 Oct 30;72(9):1114-31 [16934762.001]
  • [Cites] EMBO Rep. 2006 Oct;7(10):1023-9 [16888650.001]
  • [Cites] Trends Immunol. 2006 Nov;27(11):533-40 [16982211.001]
  • [Cites] Ann Rheum Dis. 2006 Nov;65 Suppl 3:iii83-8 [17038480.001]
  • [Cites] Genes Dev. 2006 Oct 15;20(20):2871-86 [17043312.001]
  • [Cites] Sci STKE. 2006 Oct 17;2006(357):re13 [17047224.001]
  • [Cites] Biomed Pharmacother. 2006 Nov;60(9):520-8 [16949786.001]
  • [Cites] Oncogene. 2006 Oct 30;25(51):6706-16 [17072323.001]
  • [Cites] J Biol Chem. 1999 Oct 22;274(43):30353-6 [10521409.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Nov 2;101(44):15603-8 [15501915.001]
  • [Cites] J Leukoc Biol. 2004 Nov;76(5):1075-81 [15316034.001]
  • [Cites] Arthritis Res Ther. 2004;6(6):248-64 [15535838.001]
  • [Cites] J Allergy Clin Immunol. 2004 Nov;114(5):1059-69 [15536411.001]
  • [Cites] J Biol Chem. 2004 Nov 26;279(48):50050-9 [15355994.001]
  • [Cites] J Biol Chem. 2004 Nov 26;279(48):49571-4 [15465828.001]
  • [Cites] J Cell Sci. 2004 Dec 1;117(Pt 25):5965-73 [15564374.001]
  • [Cites] Curr Opin Nephrol Hypertens. 2005 Jan;14(1):59-66 [15586017.001]
  • [Cites] J Biol Chem. 2004 Dec 31;279(53):55633-43 [15489227.001]
  • [Cites] J Biol Chem. 2005 Jan 7;280(1):244-52 [15516339.001]
  • [Cites] Mol Pharmacol. 2002 Aug;62(2):297-303 [12130681.001]
  • [Cites] Cell. 2002 Jul 12;110(1):93-105 [12151000.001]
  • [Cites] Mol Cell Biol. 2002 Sep;22(17):6286-97 [12167720.001]
  • [Cites] Endocrinology. 2002 Sep;143(9):3482-9 [12193561.001]
  • [Cites] Am J Respir Cell Mol Biol. 2002 Sep;27(3):320-8 [12204894.001]
  • [Cites] FASEB J. 2001 Apr;15(6):1110-2 [11292684.001]
  • [Cites] Hum Mol Genet. 2002 Oct 1;11(20):2371-5 [12351572.001]
  • [Cites] Mol Endocrinol. 2002 Oct;16(10):2382-92 [12351702.001]
  • [Cites] J Biol Chem. 2005 Feb 25;280(8):6349-58 [15556937.001]
  • [Cites] Biochem Cell Biol. 2005 Feb;83(1):1-14 [15746962.001]
  • [Cites] J Biol Chem. 2005 Mar 18;280(11):9957-62 [15642694.001]
  • [Cites] J Biol Chem. 2005 Mar 25;280(12):11120-6 [15657031.001]
  • [Cites] J Biol Chem. 2005 Mar 25;280(12):11192-202 [15671023.001]
  • [Cites] J Biol Chem. 2005 Apr 1;280(13):13187-94 [15677482.001]
  • [Cites] Biochem J. 2005 Apr 15;387(Pt 2):507-17 [15568999.001]
  • [Cites] Bioorg Med Chem Lett. 2005 Apr 15;15(8):2163-7 [15808489.001]
  • [Cites] J Exp Med. 2005 Apr 4;201(7):1169-77 [15809356.001]
  • [Cites] Cancer Biol Ther. 2004 Oct;3(10):1007-17 [15467434.001]
  • [Cites] Nat Immunol. 2005 May;6(5):439-45 [15843800.001]
  • [Cites] EMBO J. 2005 Mar 23;24(6):1157-69 [15775976.001]
  • [Cites] J Biol Chem. 2005 Apr 29;280(17):17435-48 [15722553.001]
  • [Cites] Mol Cell Biol. 2005 May;25(10):4150-65 [15870285.001]
  • [Cites] Genes Dev. 2005 May 1;19(9):1116-27 [15879558.001]
  • [Cites] J Biol Chem. 2005 May 13;280(19):18842-52 [15708845.001]
  • [Cites] J Cell Sci. 2005 May 15;118(Pt 10):2247-59 [15870105.001]
  • [Cites] Oncogene. 2005 May 12;24(21):3492-502 [15735677.001]
  • [Cites] Endocr Rev. 2005 May;26(3):452-64 [15814846.001]
  • [Cites] Endocr Rev. 2005 May;26(3):393-9 [15814849.001]
  • [Cites] Curr Opin Pharmacol. 2005 Jun;5(3):264-71 [15907913.001]
  • [Cites] Mol Endocrinol. 2005 Jun;19(6):1501-15 [15705660.001]
  • [Cites] Mol Endocrinol. 2005 Jun;19(6):1569-83 [15817653.001]
  • [Cites] Hum Mol Genet. 2005 Aug 1;14(15):2247-56 [16002417.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Aug 26;334(2):638-45 [16009338.001]
  • [Cites] Nat Cell Biol. 2005 Aug;7(8):758-65 [16056267.001]
  • [Cites] Bioorg Med Chem Lett. 2007 Jun 15;17(12):3354-61 [17467988.001]
  • [Cites] Cell Signal. 2007 Jul;19(7):1419-33 [17317104.001]
  • [Cites] Cell Signal. 2007 Jul;19(7):1372-82 [17512700.001]
  • [Cites] Genes Dev. 2007 Jun 1;21(11):1396-408 [17510282.001]
  • [Cites] J Clin Invest. 2007 Jun;117(6):1605-15 [17492054.001]
  • [Cites] Neuroendocrinology. 2007;85(3):186-92 [17446698.001]
  • [Cites] Cell. 2007 Jun 15;129(6):1125-40 [17574025.001]
  • [Cites] Nature. 2007 Jun 21;447(7147):972-8 [17538624.001]
  • [Cites] Endocr Metab Immune Disord Drug Targets. 2007 Jun;7(2):125-40 [17584152.001]
  • [Cites] Mol Endocrinol. 2007 Jul;21(7):1552-68 [17440046.001]
  • [Cites] Pharmacol Res. 2007 Jun;55(6):545-59 [17582782.001]
  • [Cites] EMBO J. 2007 Jul 11;26(13):3075-85 [17568772.001]
  • [Cites] J Biol Chem. 2007 Jul 20;282(29):21308-18 [17537731.001]
  • [Cites] Endocrinology. 2007 Aug;148(8):3958-67 [17510235.001]
  • [Cites] Cell Mol Life Sci. 2007 Aug;64(15):1979-96 [17530464.001]
  • [Cites] Mol Endocrinol. 2007 Aug;21(8):1924-39 [17519355.001]
  • [Cites] PLoS Genet. 2007 Jun;3(6):e94 [17559307.001]
  • [Cites] J Biol Chem. 2007 Aug 17;282(33):24120-30 [17581824.001]
  • [Cites] Mol Cell Endocrinol. 2007 Sep 15;275(1-2):79-97 [17561338.001]
  • [Cites] Immunol Rev. 2005 Dec;208:126-40 [16313345.001]
  • [Cites] EMBO J. 2006 Jan 11;25(1):108-17 [16362036.001]
  • [Cites] J Biol Chem. 2006 Jan 13;281(2):915-26 [16286470.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):929-35 [16424027.001]
  • [Cites] Curr Opin Genet Dev. 2006 Feb;16(1):65-70 [16377173.001]
  • [Cites] J Immunol. 2006 Feb 1;176(3):1899-907 [16424221.001]
  • [Cites] Nat Immunol. 2006 Feb;7(2):148-55 [16415872.001]
  • [Cites] J Exp Med. 2006 Jan 23;203(1):7-13 [16380507.001]
  • [Cites] J Exp Med. 2006 Jan 23;203(1):15-20 [16380512.001]
  • [Cites] J Exp Med. 2006 Jan 23;203(1):131-40 [16380513.001]
  • [Cites] J Exp Med. 2006 Jan 23;203(1):189-201 [16390935.001]
  • [Cites] J Biol Chem. 1998 Jan 23;273(4):1998-2007 [9442036.001]
  • [Cites] J Biol Chem. 1998 Jan 23;273(4):2008-14 [9442037.001]
  • [Cites] J Biol Chem. 1998 Feb 6;273(6):3129-31 [9452419.001]
  • [Cites] J Biol Chem. 1998 Feb 6;273(6):3285-90 [9452444.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2050-5 [9482836.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Mar;83(3):1016-9 [9506766.001]
  • [Cites] Mol Endocrinol. 1998 Mar;12(3):355-63 [9514153.001]
  • [Cites] Endocrinology. 1998 Apr;139(4):1653-61 [9528946.001]
  • [Cites] J Biol Chem. 2006 Mar 10;281(10):6175-83 [16407239.001]
  • [Cites] Eur J Pharmacol. 2006 Mar 8;533(1-3):2-14 [16436275.001]
  • [Cites] Genes Dev. 2006 Mar 15;20(6):689-99 [16543221.001]
  • [Cites] Ernst Schering Res Found Workshop. 2006;(57):173-92 [16568955.001]
  • [Cites] Eur J Pharmacol. 2006 Apr 24;536(1-2):12-8 [16564041.001]
  • [Cites] Mol Pharmacol. 2006 May;69(5):1763-71 [16489124.001]
  • [Cites] Diabetes. 2006 May;55(5):1380-90 [16644695.001]
  • [Cites] Bone. 2006 May;38(5):652-61 [16298558.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4610-6 [16651411.001]
  • [Cites] Cell Signal. 2006 Aug;18(8):1309-17 [16303288.001]
  • [Cites] Biochemistry. 2006 May 30;45(21):6733-40 [16716084.001]
  • [Cites] Genes Dev. 2006 Jun 1;20(11):1405-28 [16751179.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2006 Jul;291(1):L11-8 [16489115.001]
  • [Cites] J Biol Chem. 2006 Jun 16;281(24):16821-32 [16624805.001]
  • [Cites] Tissue Antigens. 2006 Jul;68(1):1-12 [16774534.001]
  • [Cites] Endocrinology. 2006 Jul;147(7):3555-62 [16574792.001]
  • [Cites] Trends Cell Biol. 2006 Jun;16(6):301-7 [16697199.001]
  • [Cites] Allergy. 2006 Jul;61(7):886-90 [16792589.001]
  • [Cites] J Leukoc Biol. 2006 Jul;80(1):133-44 [16670125.001]
  • [Cites] J Biol Chem. 2006 Jul 7;281(27):18684-90 [16675465.001]
  • [Cites] J Biol Chem. 2006 Jul 7;281(27):18482-8 [16684768.001]
  • [Cites] J Med Chem. 2006 Jul 13;49(14):4216-31 [16821781.001]
  • [Cites] Curr Opin Pharmacol. 2006 Aug;6(4):387-92 [16781194.001]
  • [Cites] Cytokine Growth Factor Rev. 2006 Aug;17(4):281-93 [16793322.001]
  • [Cites] J Immunol. 2006 Aug 15;177(4):2047-50 [16887961.001]
  • [Cites] J Allergy Clin Immunol. 2006 Aug;118(2):368-75 [16890760.001]
  • [Cites] Mol Cell Biol. 2008 Apr;28(8):2840-9 [18268010.001]
  • [Cites] J Endocrinol. 2008 Apr;197(1):1-10 [18372227.001]
  • [Cites] J Cell Biochem. 2008 Apr 15;103(6):1760-71 [17910039.001]
  • [Cites] Front Neuroendocrinol. 2008 May;29(2):273-91 [18054070.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Apr 15;105(15):5745-9 [18408151.001]
  • [Cites] Endocrinology. 2008 May;149(5):2080-9 [18218700.001]
  • [Cites] Arthritis Res Ther. 2008;10(1):201 [18226189.001]
  • [Cites] Genes Dev. 2008 May 1;22(9):1159-73 [18408078.001]
  • [Cites] J Clin Endocrinol Metab. 2008 May;93(5):1563-72 [18319312.001]
  • [Cites] Mol Cell Biol. 2008 Jun;28(11):3623-38 [18362169.001]
  • [Cites] J Biol Chem. 2008 May 23;283(21):14277-85 [18356163.001]
  • [Cites] Front Biosci. 2008;13:5866-79 [18508628.001]
  • [Cites] Mol Endocrinol. 2008 Jun;22(6):1320-30 [18308897.001]
  • [Cites] Mol Endocrinol. 2008 Jun;22(6):1331-44 [18337589.001]
  • [Cites] J Immunol. 2008 Jun 15;180(12):8342-53 [18523301.001]
  • [Cites] Cell Cycle. 2008 May 15;7(10):1336-42 [18418070.001]
  • [Cites] Curr Top Med Chem. 2008;8(9):750-65 [18537686.001]
  • [Cites] J Exp Med. 2008 Jun 9;205(6):1491-503 [18504304.001]
  • [Cites] Epigenetics. 2008 Mar-Apr;3(2):97-106 [18536531.001]
  • [Cites] Oncogene. 2006 Oct 30;25(51):6717-30 [17072324.001]
  • [Cites] Oncogene. 2006 Oct 30;25(51):6868-86 [17072333.001]
  • [Cites] Biochem Soc Trans. 2006 Dec;34(Pt 6):1018-23 [17073741.001]
  • [Cites] Mol Cell. 2006 Nov 3;24(3):341-54 [17081986.001]
  • [Cites] Mol Cell. 2006 Nov 3;24(3):367-81 [17081988.001]
  • [Cites] J Cell Sci. 2006 Nov 15;119(Pt 22):4607-15 [17093265.001]
  • [Cites] J Biol Chem. 1997 Dec 5;272(49):30709-14 [9388207.001]
  • [Cites] Mol Cell Biol. 2006 Dec;26(23):9126-35 [16982682.001]
  • [Cites] Endocrinology. 2006 Dec;147(12):5549-56 [16946006.001]
  • [Cites] Mol Pharmacol. 2006 Dec;70(6):2084-95 [16988013.001]
  • [Cites] J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):11-21 [17070034.001]
  • [Cites] J Biol Chem. 2005 Jan 21;280(3):2388-94 [15537647.001]
  • [Cites] Cancer Res. 2005 Jan 15;65(2):457-64 [15695387.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2005 Mar;288(3):R567-74 [15576665.001]
  • [Cites] Biochemistry. 2005 Feb 15;44(6):2030-8 [15697228.001]
  • [Cites] J Biol Chem. 2005 Feb 18;280(7):5178-87 [15563468.001]
  • [Cites] Endocrinology. 2005 Mar;146(3):1391-7 [15576458.001]
  • [Cites] Mol Pharmacol. 2005 Mar;67(3):815-26 [15550679.001]
  • [Cites] Mol Pharmacol. 2005 Mar;67(3):598-603 [15608142.001]
  • [Cites] Mol Cell Endocrinol. 2007 Jan 29;264(1-2):164-70 [17182172.001]
  • [Cites] Blood. 2007 Feb 1;109(3):1265-74 [17018861.001]
  • [Cites] EMBO J. 2007 Jan 24;26(2):436-47 [17183367.001]
  • [Cites] Nucleic Acids Res. 2007;35(2):517-28 [17169985.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Mar 9;354(2):603-7 [17240358.001]
  • [Cites] J Biol Chem. 2007 Feb 9;282(6):4021-34 [17095510.001]
  • [Cites] Biochem J. 2007 Mar 15;402(3):491-501 [17117922.001]
  • [Cites] N Engl J Med. 2007 Feb 22;356(8):775-89 [17314337.001]
  • [Cites] Mol Endocrinol. 2007 Mar;21(3):625-34 [17185395.001]
  • [Cites] Cell Signal. 2007 Apr;19(4):695-704 [17052890.001]
  • [Cites] J Clin Invest. 2007 Mar;117(3):773-83 [17332896.001]
  • [Cites] Mol Cell Biol. 2007 Apr;27(7):2442-51 [17261597.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2007 Apr;48(4):1724-34 [17389505.001]
  • [Cites] Genes Dev. 2007 Apr 1;21(7):744-9 [17403776.001]
  • [Cites] Trends Mol Med. 2007 Apr;13(4):158-63 [17293163.001]
  • [Cites] Curr Opin Rheumatol. 2007 May;19(3):238-45 [17414949.001]
  • [Cites] J Biol Chem. 2007 Apr 13;282(15):10963-71 [17314103.001]
  • [Cites] J Mol Biol. 2007 May 4;368(3):729-41 [17367809.001]
  • [Cites] Mol Cell. 2007 Apr 13;26(1):75-87 [17434128.001]
  • [Cites] J Biol Chem. 2007 Apr 27;282(17):12566-73 [17337450.001]
  • [Cites] Blood. 2007 May 15;109(10):4313-9 [17255352.001]
  • [Cites] Arthritis Rheum. 2007 May;56(5):1629-37 [17469145.001]
  • [Cites] Oncogene. 2007 May 14;26(22):3240-53 [17496919.001]
  • [Cites] J Immunol. 2007 Jun 1;178(11):7366-75 [17513787.001]
  • [Cites] Stress. 2007 Jun;10(2):213-9 [17514590.001]
  • [Cites] Steroids. 2007 Jun;72(6-7):600-8 [17509631.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10762-7 [18669648.001]
  • [Cites] Eur J Pharmacol. 2008 Sep 4;591(1-3):231-6 [18577381.001]
  • [Cites] Nat Immunol. 2008 Sep;9(9):1028-36 [18690222.001]
  • [Cites] Cell Signal. 2008 Oct;20(10):1780-6 [18611438.001]
  • [Cites] Thorax. 2008 Sep;63(9):784-90 [18492738.001]
  • [Cites] Mol Endocrinol. 2008 Sep;22(9):2061-75 [18562626.001]
  • [Cites] J Allergy Clin Immunol. 2008 Sep;122(3):550-9.e3 [18774390.001]
  • [Cites] Br J Pharmacol. 2008 Sep;155(2):152-69 [18641677.001]
  • [Cites] Gene. 2008 Nov 1;423(2):97-107 [18718859.001]
  • [Cites] J Biol Chem. 2008 Sep 19;283(38):25765-9 [18541529.001]
  • [Cites] Stress. 2008 Sep;11(5):321-38 [18609295.001]
  • [Cites] Biochemistry. 2008 Sep 30;47(39):10471-80 [18771283.001]
  • [Cites] Cell Mol Life Sci. 2008 Oct;65(19):2964-78 [18535784.001]
  • [Cites] J Mol Endocrinol. 2008 Oct;41(4):239-49 [18682532.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):15028-33 [18806225.001]
  • [Cites] Sci Signal. 2008;1(41):pe44 [18922786.001]
  • [Cites] Am J Respir Cell Mol Biol. 2008 Nov;39(5):543-50 [18474669.001]
  • [Cites] Trends Endocrinol Metab. 2008 Nov;19(9):331-9 [18805703.001]
  • [Cites] Nat Rev Immunol. 2008 Nov;8(11):837-48 [18927578.001]
  • [Cites] Mol Cell Endocrinol. 2007 Sep 15;275(1-2):30-42 [17576036.001]
  • [Cites] Mol Cell Endocrinol. 2007 Sep 15;275(1-2):98-108 [17587493.001]
  • [Cites] Mol Cell Endocrinol. 2007 Sep 15;275(1-2):2-12 [17628337.001]
  • [Cites] Mol Cell Endocrinol. 2007 Sep 15;275(1-2):109-17 [17630119.001]
  • [Cites] Mol Cell Endocrinol. 2007 Sep 15;275(1-2):13-29 [17689856.001]
  • [Cites] J Leukoc Biol. 2007 Sep;82(3):700-9 [17576820.001]
  • [Cites] Cell Physiol Biochem. 2007;20(5):527-34 [17762179.001]
  • [Cites] FASEB J. 2007 Sep;21(11):2642-54 [17431096.001]
  • [Cites] Clin Exp Immunol. 2007 Oct;150(1):151-7 [17711487.001]
  • [Cites] Am J Respir Cell Mol Biol. 2007 Oct;37(4):457-66 [17556672.001]
  • [Cites] J Immunol. 2007 Oct 1;179(7):4598-607 [17878357.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2274-9 [16461893.001]
  • [Cites] Mol Cell Endocrinol. 2006 Feb 26;246(1-2):142-6 [16388891.001]
  • [Cites] Blood. 2006 Mar 1;107(5):2061-9 [16293608.001]
  • [Cites] Blood. 2006 Mar 1;107(5):2037-44 [16293609.001]
  • [Cites] EMBO J. 2006 Feb 22;25(4):798-810 [16467852.001]
  • [Cites] Mol Endocrinol. 2006 Mar;20(3):560-72 [16239257.001]
  • [Cites] Mol Cell Biol. 2006 Mar;26(6):2399-407 [16508014.001]
  • [Cites] Mol Cell Biol. 2006 Mar;26(6):2408-18 [16508015.001]
  • [Cites] Biochem Pharmacol. 2008 Nov 15;76(10):1184-93 [18765234.001]
  • [Cites] Mol Cell Endocrinol. 2008 Nov 25;295(1-2):59-69 [18583028.001]
  • [Cites] Int J Biochem Cell Biol. 2009 Jan;41(1):176-84 [18793748.001]
  • [Cites] Blood. 2008 Dec 1;112(12):4591-7 [18791161.001]
  • [Cites] Mol Cell Biol. 2008 Dec;28(24):7309-22 [18838540.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Dec 26;377(4):1162-7 [18977197.001]
  • [Cites] Arthritis Res Ther. 2008;10(5):226 [18983693.001]
  • [Cites] Ann N Y Acad Sci. 2008 Nov;1143:1-20 [19076341.001]
  • [Cites] Clin Immunol. 2009 Jan;130(1):7-15 [18964303.001]
  • [Cites] Nucleic Acids Res. 2008 Dec;36(22):7207-18 [19004867.001]
  • [Cites] Rheumatology (Oxford). 2008 Apr;47(4):409-14 [18187523.001]
  • [Cites] Mol Pharmacol. 2007 Oct;72(4):799-809 [17622575.001]
  • [Cites] Mol Endocrinol. 2007 Oct;21(10):2403-15 [17595317.001]
  • [Cites] Pharmacol Ther. 2007 Nov;116(2):249-65 [17720252.001]
  • [Cites] Mol Cell Biol. 2007 Oct;27(20):7143-60 [17682054.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 2;104(40):15858-63 [17898169.001]
  • [Cites] J Endocrinol. 2007 Nov;195(2):229-40 [17951534.001]
  • [Cites] Pflugers Arch. 2007 Dec;455(3):493-503 [17618452.001]
  • [Cites] Nature. 2007 Oct 25;449(7165):1073-7 [17960246.001]
  • [Cites] Mol Endocrinol. 2007 Nov;21(11):2663-71 [17636038.001]
  • [Cites] J Biol Chem. 2007 Nov 2;282(44):32311-9 [17728246.001]
  • [Cites] Mol Endocrinol. 2007 Dec;21(12):2929-40 [17761948.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Dec;92(12):4514-21 [17895323.001]
  • [Cites] Brain Behav Immun. 2008 Jan;22(1):42-51 [17716859.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19244-9 [18032610.001]
  • [Cites] Curr Opin Immunol. 2007 Dec;19(6):694-700 [17720468.001]
  • [Cites] J Med Chem. 2007 Dec 27;50(26):6519-34 [18038970.001]
  • [Cites] Mol Pharmacol. 2008 Jan;73(1):203-14 [17901197.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2008;48:1-32 [17608617.001]
  • [Cites] EMBO J. 2008 Jan 9;27(1):88-99 [18059471.001]
  • [Cites] Cancer Genomics Proteomics. 2007 Nov-Dec;4(6):387-98 [18204201.001]
  • [Cites] J Immunol. 2008 Feb 15;180(4):2608-15 [18250472.001]
  • [Cites] Cell. 2008 Feb 8;132(3):344-62 [18267068.001]
  • [Cites] Trends Mol Med. 2007 Nov;13(11):460-9 [18029230.001]
  • [Cites] Mol Immunol. 2008 Apr;45(7):1995-2006 [18061676.001]
  • [Cites] Cell Signal. 2008 Apr;20(4):771-8 [18249093.001]
  • [Cites] Mol Endocrinol. 2008 Mar;22(3):585-96 [18079322.001]
  • [Cites] Nature. 2008 Mar 6;452(7183):45-50 [18322525.001]
  • [Cites] Nature. 2008 Mar 6;452(7183):112-5 [18322535.001]
  • [Cites] J Steroid Biochem Mol Biol. 2008 Mar;109(1-2):150-7 [18304804.001]
  • [Cites] Curr Opin Rheumatol. 2008 Mar;20(2):131-7 [18349741.001]
  • [Cites] Brain Res Rev. 2008 Mar;57(2):571-85 [18164765.001]
  • [Cites] Eur J Pharmacol. 2008 Apr 7;583(2-3):263-71 [18275949.001]
  • [Cites] Eur J Pharmacol. 2008 Apr 7;583(2-3):303-11 [18321483.001]
  • [Cites] Am J Respir Cell Mol Biol. 2006 Dec;35(6):668-80 [16809634.001]
  • [Cites] Cytokine Growth Factor Rev. 2008 Jun-Aug;19(3-4):187-97 [18515173.001]
  • [Cites] EMBO J. 2008 Jun 18;27(12):1682-93 [18511904.001]
  • [Cites] Endocrinology. 2008 Jul;149(7):3635-42 [18403484.001]
  • [Cites] Trends Immunol. 2008 Jul;29(7):329-36 [18534908.001]
  • [Cites] Trends Biochem Sci. 2008 Jul;33(7):339-49 [18585916.001]
  • [Cites] Endocrinology. 2008 Aug;149(8):3900-8 [18467435.001]
  • [Cites] Mol Endocrinol. 2008 Aug;22(8):1754-66 [18483179.001]
  • [Cites] Mol Endocrinol. 2008 Aug;22(8):1767-80 [18535250.001]
  • [Cites] Genes Dev. 2008 Aug 1;22(15):2093-101 [18676814.001]
  • [Cites] J Biol Chem. 2008 Aug 8;283(32):22089-96 [18524780.001]
  • [Cites] Int J Biochem Cell Biol. 2008;40(11):2358-62 [17951098.001]
  • [Cites] Pharmacol Rev. 2006 Dec;58(4):685-704 [17132848.001]
  • [Cites] Brain Behav Immun. 2007 Jan;21(1):9-19 [17070667.001]
  • [Cites] Neurochem Int. 2007 Jan;50(1):264-70 [17052801.001]
  • [Cites] Immunity. 2006 Dec;25(6):919-28 [17157040.001]
  • [Cites] J Biol Chem. 2006 Dec 22;281(51):39128-34 [17074751.001]
  • [Cites] Oncogene. 2007 Jan 4;26(1):1-10 [16799638.001]
  • [Cites] J Allergy Clin Immunol. 2007 Jan;119(1):115-22 [17208592.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Jan;292(1):C396-404 [16971495.001]
  • (PMID = 19890091.001).
  • [ISSN] 1945-7189
  • [Journal-full-title] Endocrine reviews
  • [ISO-abbreviation] Endocr. Rev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA020535; United States / NCI NIH HHS / CA / R37 CA020535; United States / NCI NIH HHS / CA / CA020535
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / Protein Kinase Inhibitors; 0 / Receptors, Glucocorticoid; EC 2.7.- / Protein Kinases; EC 3.1.3.- / Phosphoric Monoester Hydrolases
  • [Number-of-references] 699
  • [Other-IDs] NLM/ PMC2818158
  •  go-up   go-down


25. America's best children's hospitals. US News World Rep; 2008 Jun 9;144(16):41-2, 44, 46 passim

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Anecdotes as Topic. Child. Child, Preschool. Female. Hemosiderosis / complications. Humans. Hypoplastic Left Heart Syndrome / surgery. Infant. Infant, Newborn. Intensive Care, Neonatal. Intestinal Atresia / drug therapy. Lung Diseases / etiology. Lung Diseases / surgery. Lung Transplantation. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. United States

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18683458.001).
  • [ISSN] 0041-5537
  • [Journal-full-title] U.S. news & world report
  • [ISO-abbreviation] US News World Rep
  • [Language] eng
  • [Publication-type] News
  • [Publication-country] United States
  •  go-up   go-down






Advertisement